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Preface 
This dissertation is presented in an article format. The findings of the study are presented in chapter 
three and chapter four as manuscripts, as required by the regulations of the University of KwaZulu-
Natal. The manuscript in chapter three has been submitted for publication to Health SA Gesondheid. 
The systematic review manuscript in chapter four has been submitted for publication to BMC 
Systematic Reviews. The references used in the manuscripts were cited according to the instructions/ 
guidelines for authors as required by the journals. 
This dissertation consists of five chapters as follows: 
Chapter 1: Provides an introduction and explains the rationale and significance of the study. The aims, 
objectives, and methodology of the study are also highlighted. 
Chapter 2: Comprises of existing literature and highlights the prevalence of infection as well as the 
use, safety, and risk perception of antibiotics in pregnancy. 
Chapter 3: Manuscript I entitled, ‘’Antibiotic use among pregnant women: KwaZulu-Natal‘’ was 
written according to the author guidelines and submitted for publication to Health SA Gesondheid. 
Chapter 4: Manuscript II entitled, ‘’Awareness and risk perception of antibiotic use among pregnant 
women: A mixed-methods systematic review’’ was written according to the author guidelines and 
submitted for publication to BMC Systematic Reviews. 
Chapter 5: Provides a summary of the findings, future recommendations, limitations, and strengths of 
the study with a general conclusion. 
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Abstract 
Background 
Antibiotic therapy in pregnant women has significantly increased in the effort to reduce maternal and 
neonatal deaths. However, antibiotic exposure may negatively affect the developing foetus. 
Information on the use, safety, and impact of antibiotics on birth outcomes and maternal-foetal health 
in low and middle-income countries are limited. This study aims to evaluate the use of antibiotics 
among pregnant women by quantifying antibiotic use and commenting on their safety profile. 
Furthermore, the risk perception of antibiotics among pregnant women, across all geographic regions, 
were determined.  
Method 
Patient demographics and treatment information were obtained from MediTech®; an electronic 
patient information database, from January 2019 to July 2019. Descriptive and analytical measures 
were used to describe both patient demographics and antibiotic treatment variables. A systematic 
review was conducted to determine the risk perception of antibiotics among pregnant women. A 
systematic search for studies from January 2000 to December 2019 were performed using four 
databases, which included: PubMed, Scopus, CINAHL, and Psycinfo. The systematic review involved 
the categorisation of data into relevant themes and sub-themes; data transformation and outcomes 
were discussed using narrative and thematic synthesis. 
Results 
A total of 416 antibiotic prescriptions, issued to 184 patients, were reviewed. Penicillins (39.7%), 
macrolides (13.0%), and combination penicillin-and-beta-lactam inhibitors (12.3%) were reported as 
the most commonly prescribed antibiotics in pregnancy. Most antibiotics were prescribed for diseases 
of the circulatory system (36.1%). A significant correlation was found between the duration of therapy 
and the age of the patient (>20, p=0.0009, 20-29, p=0.017, 30-42, p=0.03). The systematic review 
identified a total of 1539 articles, of which 14 studies met the inclusion criteria. The selected studies 
 
 
xvi 
 
included four regions: Europe, America, Asia, and Africa. Limited studies were found in low and 
middle-income countries, especially among rural communities. 
Conclusion 
Penicillins remain as the most common antibiotic used in pregnant women. However, the use of other 
antibiotic classes apart from the commonly used beta-lactams are also increasing, showing evidence 
of antibiotic resistance. In addition, the influence of perception significantly affects antibiotic use 
among pregnant women.  
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Chapter 1: Introduction 
Chapter one provides the overall context for the study. The background of the study, the problem 
statement, and rationale of the study are mentioned. The aim, objectives, and a brief methodology 
are also included. 
1.1 Background 
Pharmacoepidemiology is defined as, “the study of the uses and effects of drugs in well-defined 
populations’’ (Yang and West-Strum, 2010). Pharmacoepidemiology studies, quantify and study drug 
use patterns, the appropriateness of use, drug safety, medication adherence, and identify predictors 
for medication use. It involves the use of pharmacokinetic and pharmacodynamic studies to predict 
the effect of a drug on the patient (Yang and West-Strum, 2010). These studies also allow for the 
identification of the contributory factors that determine the occurrence and distribution of diseases 
in specific populations (Torre and Martins, 2012). 
Pharmacovigilance and drug safety are key elements of pharmacoepidemiology (Yang and West-
Strum, 2010). Pharmacovigilance is defined by the World Health Organization (WHO) as, “the science 
and activities relating to the detection, assessment, understanding, and prevention of adverse effects, 
or any other drug-related problem” (World Health Organization, 2002). Pharmacovigilance is a critical 
component for determining the benefit to risk ratio of medicines. The goal of pharmacovigilance is to 
promote the rational and safe use of medicines, minimise the risks, and maximise the benefit of 
medicine use (Jalali, 2018).  
Pharmacotherapy in pregnant women is currently not optimised (Stock and Norman, 2019). The 
involvement of pregnant participants in drug studies has been negligible for a considerable period. 
This exclusion is due to the risk of potential fetotoxicity. Fetotoxicity refers to “the functional changes 
that can occur to the foetus as a result of medication use’’ (Henderson and Mackillop, 2011). Thus, 
the available safety information and clinical evidence for medicine use in pregnant women are limited. 
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Many studies on drug use in pregnancy are therefore retrospective. These study types can only 
determine associations between exposure and the possibility of potential side effects (Crider et al., 
2009).  
Drugs cannot be classified as teratogens without careful consideration of the dose, route, duration, 
and gestational period of the treatment (Polifka and Friedman, 2002). Treatments commonly used in 
pregnancy are thus often out-dated and untested, not optimised in dose, and are often prescribed 
without adequate safety information (Polifka and Friedman, 2002; Adam et al., 2011).  
Antibiotics are the most frequently prescribed drugs in pregnancy as the treatment of infection is 
critical to the health of both the mother and foetus (Mensah et al., 2017). However, only a few classes 
of antibiotics have an established safety-record with studies been conducted to evaluate the direct 
link between the drug and major congenital malformations (Lamont, Blogg, and Lamont, 2014). There 
have been a few studies that have investigated the short-and-long-term effects of common antibiotics 
on the foetus and have published new safety data, highlighting the benefits and concerns of antibiotic 
therapy (Broe et al., 2014; Lamont, Blogg, and Lamont, 2014). 
The perception of risk is a multidimensional concept that could potentially adversely affect 
pharmacotherapy. Risk perception is defined as ‘’beliefs about the potential harm or the possibility 
of a loss’’ (Molina et al., 2013). The subjective judgment that people make about the characteristics 
and severity of risk could affect adherence, compromising the health and safety of the mother and 
foetus (Molina et al., 2013). All pregnancies have a 2-3% risk of congenital anomalies but unrealistic 
perception may have detrimental effects on maternal-foetal health (Hollier, 2000). The study of risk 
perception is pertinent to understanding how women perceive the use of medicines to ensure safety 
and efficacy (Alemu and Wolle, 2019).  
Antibiotic use is significantly increasing in pregnant women (Broe et al., 2014). The quantification of 
antibiotics among a population of pregnant women allows for the identification of prescribing 
patterns and the review of current safety data. Additionally, the study of antibiotic risk perception 
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significantly contributes to the improvement of maternal health. This study highlights the need for the 
continuous assessment of antibiotic safety profiles and the role of perception of medicine safety in 
pharmacotherapy. 
1.2 Problem statement  
Currently, there is no standardised approach to the rational, safe, and effective use of antibiotics in 
pregnant women. Ethical concerns limit the availability of clinical evidence that is available in this 
population. Prescribers use a risk-benefit approach to treat pregnant patients based on the trimester 
of pregnancy, the severity of the illness, and potential foetal risk. The emerging crisis of antibiotic 
resistance significantly affects the use of antibiotics in pregnant women with the overuse and misuse 
of these drugs being key drivers of Antimicrobial Resistance (AMR). The epidemic of AMR is changing 
the way antibiotics are used, increasing mortality and morbidity, and greatly increasing the cost of 
health care. The management and use of antibiotics have clinical, economic, and environmental 
implications.  
1.3 Rationale and significance of the study  
The rationale for this study was to evaluate the use of antibiotics in pregnant women. This study 
provides an overview of the currently prescribed antibiotics used among pregnant women in a public 
health care facility and comments on the appropriateness of the drug, dosage, route, and safety to 
ensure rational, safe, and effective drug use.  
1.4 Aims and objectives  
The aim is to evaluate the use of antibiotics among pregnant women. This was achieved through the 
following objectives: 
• To quantify antibiotic use in pregnant patients in a public healthcare facility. 
• To comment on the rationale for antibiotic use among pregnant patients. 
• To evaluate the safety profile of antibiotics used during pregnancy. 
 
4 
 
• To determine the risk perception of antibiotic use among pregnant women in low, middle, 
and high-income countries. 
1.5 Methodology 
1.5.1 Study design 
A retrospective quantitative study was done to describe antibiotic use among pregnant women in a 
public sector hospital. Furthermore, the perception of antibiotic use among pregnant women was 
determined through a systematic review.  
1.5.2 Data Source 
Patient demographics and treatment information was obtained from MediTech®, an electronic patient 
information database, utilised by the study site. The study site was a tertiary-quaternary public sector 
hospital, located in one of the metropolitan areas of South Africa. This large-scale hospital functions 
electronically and is the first hospital to have developed a public/ private affiliation in the provision of 
patient care and services. Data were collected for a period of seven-months.  
1.5.3 Data collection 
A data collection template was developed and the necessary information was extracted from 
MediTech®. The information was recorded on a workbook in Microsoft Excel®. Data extracted included 
patient demographics and information on antibiotic use; name, dose, route of administration, 
frequency of administration, and duration of treatment. 
1.5.4 Data analysis 
Descriptive and analytical measures were used to describe both patient demographics and antibiotic 
treatment variables. Data analysed were presented in the form of frequency tables and graphs. 
Quantitative data such as patient demographic data were analysed in terms of descriptive statistics. 
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The HIV status of the patients was also considered. The class of the antibiotic used in pregnant patients 
were highlighted to examine whether antibiotic use was rational and safe. 
1.5.5 Data Management 
Data collected were stored on a password-protected computer. Data will be removed upon completed 
dissemination of results.  
1.5.6. Systematic Review 
The Joanna Briggs Institute (JBI) guidelines for mixed-methods systematic reviews (MMSRs) and the 
Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines were followed (Johanna Brigg 
Institute, 2019). A systematic search for studies from January 2000 to December 2019 was performed 
using four databases, which included: PubMed, Scopus, CINAHL, and Psycinfo. A data extraction 
template was used to record; the author’s name, year of publication, country, setting, study design, 
socio-demographic description, sample size, and the main findings. The systematic review involved 
the categorisation of data into relevant themes and sub-themes; data transformation and outcomes 
were discussed using narrative and thematic synthesis.  
1.6 Confidentiality 
All information was kept confidential. Patient names were coded. Individual patients’ written 
informed consent for the data extraction was not needed, as only anonymised, retrospective data 
were utilised. 
1.7 Ethical approval 
Ethical approval was obtained from the Biomedical Research and Ethics Committee (BREC) located at 
the University of KwaZulu-Natal (UKZN); (ethical approval number: BE330/19 - Annexure 1), KZN 
Department of Health (KZN-DoH), and Inkosi Albert Luthuli Central Hospital (IALCH). Ethical clearance 
was not required to perform the systematic review.  
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Chapter summary 
This chapter has provided an outline of the study. The significance of the research, aim, objectives, 
and methodology of the study are discussed. The following chapter provides a theoretical basis for 
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
References 
Adam, M. P., Polifka, J. E., and Friedman, J. M., 2011. Evolving knowledge of the teratogenicity of 
medications in human pregnancy. In American Journal of Medical Genetics, Part C: Seminars in 
Medical Genetics, 157(3), pp. 175–182. 
Alemu, B. K. and Wolle, N. N., 2019. Prescription drug use and potential teratogenicity risk among 
pregnant women attending maternal and child health clinic of Kemisse General Hospital, Northeast, 
Ethiopia. BMC Research Notes, 12(1), p. 592.  
Broe, A., Pottegard, A., Lamont, R. F., Jorgensen, J. S., and Damkier, P., 2014. Increasing use of 
antibiotics in pregnancy during the period 2000–2010: Prevalence, timing, category, and 
demographics. BJOG: An International Journal of Obstetrics and Gynaecology, 121(8), pp. 988-996. 
Crider, K. S., Cleves, M. A., Reefhuis, J., Berry, R. J., Hobbs, C. A., and Hu, D. J., 2009. Antibacterial 
medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. 
Archives of Paediatrics and Adolescent Medicine, 163(11), pp. 978-985. 
Henderson, E. and Mackillop, L., 2011. Prescribing in pregnancy and during breast feeding: Using 
principles in clinical practice. Postgraduate Medical Journal, 87(1027), pp. 349–354. 
Hollier, L. M., 2000. Maternal age and malformations in singleton births. Obstetrics and 
Gynaecology, 96(5), pp. 701–706. 
Jalali, R. K., 2018. Pharmacovigilance and drug safety. In Pharmaceutical Medicine and Translational 
Clinical Research, pp. 403–406. Academic Press. 
Johanna Brigg Institute, 2019. JBI’s Reviewer Manual, Johanna Briggs Institute, viewed 08 September 
2019, 
<https://wiki.joannabriggs.org/display/MANUAL/8.4+Developing+a+mixed+methods+review+protoc
ol%0D>. 
 
8 
 
Lamont, H. F., Blogg, H. J., and Lamont, R. F., 2014. Safety of antimicrobial treatment during 
pregnancy: A current review of resistance, immunomodulation, and teratogenicity. Expert Opinion 
on Drug Safety, 13(12), pp. 1569–1581.  
Mensah, K. B., Opoku-Agyeman, K., and Ansah, C., 2017. Antibiotic use during pregnancy: A 
retrospective study of prescription patterns and birth outcomes at an antenatal clinic in rural Ghana. 
Journal of Pharmaceutical Policy and Practice, 10(1), pp. 4–10. 
Molina, K. M., Goltz, H. H., Kowalkouski, M. A., Hart, S. L., Latini, D., and Piper, S., 2013. Risk 
perception. Encyclopedia of Behavioural Medicine, pp. 1690–1695.  
Polifka, J. E. and Friedman, J. M., 2002. Medical genetics: Clinical teratology in the age of genomics. 
Canadian Medical Association Journal, 167(3), pp. 265–273. 
Stock, S. J. E. and Norman, J. E., 2019. Medicines in pregnancy. F1000Research, 8, pp. 1–8. 
Torre, C. and Martins, A., 2012. Overview of pharmaco-epidemiological databases in the assessment 
of medicines under real-life conditions. Epidemiology-Current Perspectives on Research and 
Practical, Intech open publisher contributors, pp. 131-54. 
World Health Organization, 2002. Safety of medicines: A guide to detecting and reporting adverse 
drug reactions: Why health professionals need to take action, viewed 20 September 2019, 
<https://apps.who.int/iris/handle/10665/67378>. 
Yang, Y. and West-Strum, D., 2010. Understanding Pharmacoepidemiology. McGraw Hill 
Professional. 
 
 
 
 
 
9 
 
Chapter 2: Literature review 
1.1 Introduction 
Chapter two provides an overview of maternal health and the implementation of universal health 
coverage in South Africa. An in-depth review of antibiotic therapy in pregnant women is provided with 
emphasis on the prevalent infections experienced in pregnancy and the modulated immune response. 
The effect of pregnancy on pharmacokinetic and pharmacodynamic properties of drugs are also 
mentioned. The risks of prescription antibiotics and the ongoing crisis of AMR is further discussed in 
this chapter. The chapter concludes with the Health Beliefs Model (HBM) and the link to risk 
perception is explained with reference to the use of antibiotics. 
1.2 Maternal health in low and middle-income countries 
Maternal health in low and middle-income countries remains relatively poor (Say et al., 2006). 
Countries, predominantly in sub-Saharan Africa and South Asia, are responsible for more than half of 
the maternal deaths that occur globally (World Health Organization, 2019b). This  global crisis is due 
to the socio-economic plight within these fragile settings that contribute to the decline in maternal 
health (Brand South Africa, 2016; World Health Organization, 2019a) . 
South Africa, similar to other middle-income countries is fraught with a high burden of disease, 
financial constraints, high unemployment rates, low educational levels, and poverty (Gous, 2019; 
Koko, 2019). The population living in poverty has drastically increased by 3.1 million in a period of four 
years with 27.7% of people being unemployed (Gous, 2019; Koko, 2019). Hence more than three 
quarter of South Africans are largely reliant on the public health care sector. This results in an over-
burdened health care system. Thus, these determinants negatively affect the level of maternal health 
care received by pregnant women (Statistics South Africa, 2017; Mathew and Mash, 2019; Tucker, 
Chalkidou, and Pillay, 2019). 
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Women in high-income countries receive on average four antenatal visits by skilled health care 
professionals, whilst also receiving postpartum care. In contrast, in low and middle-income countries 
such as South Africa, that goal is not met, with only 40% of pregnant women receiving the 
recommended visits (World Health Organization, 2019a). Women in low and middle-income countries 
have on average many more pregnancies than women in high-income countries, thus contributing to 
the high maternal mortality and morbidity rates (Say et al., 2006). Increased pregnancies are mainly 
due to the low levels of education, lack of information, and poor access to family planning (Say et al., 
2006).  
In addition, maternal mortality is higher in rural areas, among poorer and less educated communities 
(World Health Organization, 2019b). In emerging countries, conditions related to pregnancy and 
childbirth constitute the second leading cause of death among women of reproductive age, 
subsequent to the human immunodeficiency virus (HIV) and the acquired immunodeficiency 
syndrome (AIDS). Statistics illustrate a concern as 810 women died every day from preventable causes 
related to pregnancy in the year 2017 (World Health Organization, 2019b). This can be attributed to 
poor accessibility to treatment together with a shortage of skilled health care professionals to offer 
treatments, the misdiagnosis of maternal conditions, and the misuse of medicines (Statistics South 
Africa, 2017; World Health Organization, 2019).  
The socio-economic determinants that affect maternal health need to be addressed with the aid of 
global strategies in an effort to reduce maternal deaths. This can be achieved by identifying barriers 
that limit access to quality health care, ensuring that there is universal health coverage, and 
preventing inappropriate use of medicines especially those that are a result of economic challenges 
(O’Donnell, 2007). 
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1.3 Implementation of the National Health Insurance (NHI) to curb health inequalities 
The implementation of the NHI aims to achieve the countries sustainable development goals (SDG’s) 
by providing universal health coverage. Public–private collaborations can play an important role in 
alleviating resource shortages that affect the public sector population (Department of Health, 2008). 
South Africa as well as other low and middle-income countries, face several health inequalities. 
Epidemiologically, South Africans are affected by a quadruple burden of disease particularly among 
the country’s lower socio-economic population (Goyena and Fallis, 2019). HIV, AIDS, tuberculosis (TB), 
maternal and neonatal mortality, and non-communicable diseases remain prevalent among these 
countries with 99% of these deaths occurring in Africa (Goyena and Fallis, 2019).  
According to WHO, sub-Saharan Africa accounts for a significant percentage (66%) of global maternal 
deaths (World Health Organization, 2019b). Therefore, it is imperative for governments to ensure that 
women have access to quality care before, during, and after childbirth in the aid to improve the 
maternal mortality ratio (O’Donnell, 2007; Abdulai and Adams, 2016).  
Currently, 1.2 million women in South Africa fall pregnant every year (Department of Health, 2013). 
The public health sector provides services to more than one million of these women as opposed to 
the private sector that treats only 140 thousand pregnant women annually with the aid of the majority 
of the countries health professionals and health care resources (Department of Health, 2013).   
Public sector facilities are faced with countless challenges and are often criticised on their core quality 
standards. The lack of staff, long waiting times, cleanliness, stock availability, inadequate medical 
equipment, infection control, and the safety of both staff and patients are some of the problems that 
continue to persist, which compromise patient care (Matthew and Mash, 2019). These concerns 
remain as the public health care system serves the majority of the population (80%) while being under-
resourced and overburdened. The increasing burden of disease and the continuous inward migration 
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of people from rural to urban areas continue to strain the health care system (O’Donnell, 2007; 
Mathew and Mash, 2019).  
Private sector hospitals and medical schemes have always been unaffordable for the vast majority of 
South Africans, worsening over time as a result of increasing annual contribution rates (Department 
of Health, 2013). The current two-tiered health care systems subsequently expose most South Africans 
to sub-optimal conditions of health care, contributing to the inequalities in our current system. In 
addition, it is unsustainable, costly, and hospital-centric (Department of Health, 2013). 
The goal to provide a coherent and unified health system is being pursued through the phased 
introduction of the NHI by aligning the two parallel health systems. The NHI, is a health financing 
system that pools funds in the effort to provide accessible quality health services for all South Africans 
based on their health care needs, irrespective of socio-economic status (Tucker, Chalkidou, and Pillay, 
2019).  
In Africa, countries such as Ghana, Nigeria, Rwanda, Kenya, and Mali have commenced with universal 
health coverage as a key strategy to shift from high hospital expenditure towards primary care with 
the introduction of public-private partnerships to expand health coverage (Twum et al., 2018; Mathew 
and Mash, 2019).   
The populations with the greatest health care needs, including vulnerable groups such as pregnant 
women, the elderly, immunocompromised patients, and particularly those experiencing difficulties in 
obtaining care will be prioritised (O’Donnell, 2007).  
This system will allow pregnant women to access maternal health services throughout their pregnancy 
and post-delivery with safe, effective, quality, and cost- effective medicines. Universal access to basic 
health care is a highly desirable goal which must be striven for. The NHI aims to narrow the health 
gap, expand health coverage, and achieve equitable health outcomes among all South Africans 
(Benatar, 2013). 
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1.4 An overview of antibiotic therapy in pregnancy 
In low and middle-income countries, the incidence of diseases that are of bacterial origin constitute 
as a major cause of morbidity and mortality (Haak and Radyowijati, 2003). Antibiotics hold a 
fundamental role in the treatment of infection to combat mortality and morbidity rates (Haak and 
Radyowijati, 2003). 
Antibiotic use in pregnant women has increased globally. A Danish study conducted between the years 
of 1999-2000 found that 29% of pregnancies were prescribed an antibiotic (Norgaard et al., 2012). 
Subsequently, a study in Norway, found that 42.5% of women were exposed to antibiotics (Engeland 
et al., 2008). Similarly, a study by Broe et al. reported that the prevalence of systemic antibiotic 
therapy in pregnancy was found to be 41.5% (Broe et al., 2014). This validates the increasing rate of 
antibiotic use over the last two decades.  
Women receive numerous prescriptions to prevent maternal-neonatal complications and antibiotics 
account for nearly 80% of all prescription medication, commonly used to treat infections that 
frequently occur in pregnancy (Haak and Radyowijati, 2003; de Tejada, 2014; Bookstaver et al., 2015). 
However, the majority of the available antibiotics may be teratogenic and could have toxic effects on 
the developing foetus; similarly, an untreated infection may also be associated with significant foetal 
risk  (Nahum, Uhl, and Kennedy, 2006).  
Pregnant women can acquire any infection that may be encountered in a non-pregnant population, 
although the severity of the infection may substantially differ leading to unfavourable outcomes 
(Kourtis, Read, and Jamieson, 2014). As the pregnancy advances, changes in the hormonal and 
metabolic levels play a significant role in the adaptation of physiological functions with complex 
alterations in the immune system, recognising pregnancy as a risk factor (Kourtis, Read, and Jamieson, 
2014).  
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Pregnant women, therefore, constitute a vulnerable population and particular consideration is 
required when prescribing (Nahum, Uhl, and Kennedy, 2006). The use of antibiotics presents as a 
challenge, as the infection needs to be treated, but the foetus needs to be protected from the possible 
side effects of the medication (Stokholm et al., 2014). Antibiotic use during pregnancy, is therefore, 
considered to be a risk-benefit decision (Bookstaver et al., 2015). 
Antibiotic therapy in pregnancy is complex and multi-layered (Henderson and Mackillop, 2011). 
Currently there is inadequate information on the safety of medicine use in pregnancy and even the 
current risk classification systems may analyse and construe the risk of the drugs differently (Amann 
et al., 2006).  
Reported side effects of antibiotics are not the only concern with regards to their usage. The misuse 
of these agents plays a vital role in the development of antibiotic resistance, particularly in those 
antibiotics used to treat prevalent diseases. Antibiotic resistance is currently escalating and antibiotics 
that were once viable medicines have lost their efficacy (Haak and Radyowijati, 2003; de Tejada, 2014). 
In addition to safety and the concerning issue of AMR, the perception of antibiotic use among women 
also needs to be studied.  
It is imperative to analyse the determinants, the use, potential risks, and perceptions involving 
systemic antibiotic prescribing during pregnancy, which may lead to the development of more 
effective policies and programs in the future (Amann et al., 2006). 
1.4.1 The classification and prevalence of infections in pregnancy 
WHO classifies infection according to three categories; pregnancy-specific infections, infections 
exacerbated by pregnancy, and incidental infections, as shown in Table 1 (Turner, 2019). 
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Table 1 Classification of maternal infections aligned with WHO (Turner, 2019) 
 
 
 
 
 
 
 
 
 
 
 
Every pregnant woman and new-born are at risk of an infection. A recently published study by the 
WHO, Global Maternal Sepsis Study (GLOSS) conducted among 52 countries, reported that the chorion 
and amnion, the urinary tract, and the skin or soft tissue are the three most prevalent sources of 
infection among pregnant women, especially in areas where HIV/AIDS are widespread (Torgovnik, 
2020). 
Infections are the primary cause of about 35 thousand maternal deaths every year (World Health 
Organization, 2017). Infection, if left untreated, leads to sepsis. Sepsis is one of the leading causes of 
maternal mortality worldwide despite the major advances made in their treatment, killing more than 
one million new-born’s every year. The WHO recently defined maternal sepsis as, “a life-threatening 
condition causing organ dysfunction resulting from infection during pregnancy, childbirth, post-
abortion, or postpartum period’’ (World Health Organization, 2017). 
The WHO estimates that the global prevalence of maternal sepsis in developed countries was 4.4% 
among live births, while in low and middle-income countries there is currently a lack of statistical data. 
However, it is estimated that sepsis accounts for one in ten maternal deaths globally (Turner, 2019; 
Torgovnik, 2020).  
Classification of maternal deaths  
1. Pregnancy-specific infections 
Chorioamnionitis 
Endometritis 
Lactational mastitis 
Site of perineal trauma 
Surgical site, e.g. caesarean 
2. Infections exacerbated by pregnancy 
Urinary tract infections 
Influenza 
Listeriosis 
Hepatitis E 
Herpes simplex virus 
Malaria 
3. Incidental infections 
Lower respiratory tract infection 
Tuberculosis 
Sexually transmitted diseases 
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Some of the non-obstetric risk factors for sepsis are anaemia, obesity, impaired immunity, diabetes, 
hepatitis, HIV/AIDS, age, ethnicity, and low socio-economic backgrounds. The obstetric risk factors in 
pregnancy include; a history of group B Streptococcal infection, vaginal discharge, a history of pelvic 
infection, prolonged spontaneous rupture of membranes, amniocentesis, cervical cerclage, caesarean 
section, vaginal trauma, wound haematoma, and the incidence multiple pregnancies (Bamfo, 2013). 
Sexually transmitted infections (STIs), primarily of bacterial origin, are a common epidemic and pose 
as a health burden to pregnant women specifically in underprivileged countries such as Southern 
Africa and Asia (Wynn et al., 2020). STIs are aggravated by pregnancy and are associated with adverse 
neonatal outcomes that may result in pre-term birth, low-birth, or stillbirth. A systematic review by 
the Sexually Transmitted Infection Clinical Trial Group (STAR) found that the prevalence of curable STIs 
was particularly high among pregnant women in low-income countries (Wynn et al., 2020). 
Additionally, a study facilitated by WHO, found that prematurity and its associated complications were 
the largest contributor to mortality in children (Harrison and Goldenberg, 2016). The rate of preterm 
birth increased to one in ten babies in the United States and is higher among neonates of Black 
ethnicity. Almost three million stillbirths are caused by STIs and if untreated, it could lead to eye and 
lower respiratory tract infections resulting in potential corneal damage or blindness (Wynn et al., 
2020). It was also estimated that every year almost two million pregnant women are diagnosed with 
Treponema infections, whereas 520 thousand  present with  complications, such as intrauterine foetal 
death, low birth weight, and congenital syphilis in neonates (Plagens-Rotman et al., 2019). Chlamydia 
Trachomatis is also one of the most prevalent sexually transmitted bacterial infections worldwide with 
estimates that 92 million new cases occur annually (Silva et al., 2011). 
Urinary tract infections (UTIs) in pregnancy are also significantly associated with maternal morbidity 
and adverse pregnancy outcomes, including preterm birth and low birthweight. It was reported that 
pregnant women are at an increased risk of developing UTIs primarily due to a shift in the position of 
the urinary tract and hormonal changes during pregnancy enable bacteria to move up the urethra to 
 
17 
 
the kidney, which may lead to the development of bacteriuria (Demilie et al., 2012). A population-
based study, conducted among the rural inhabitants of Bangladesh, reported that the prevalence of 
UTIs among pregnant women were found to be 8.9% while 4.5% of these women were asymptomatic 
(Lee et al., 2020). The common risk factors in this population included malnutrition, primiparity, and 
low paternal education (Katona and Katona‐Apte, 2008; Schnarr and Smaill, 2008). The major uro-
pathogens were E.coli, Klebsiella, and the various Staphylococcal species (Lee et al., 2020). An 
Ethiopian hospital based prospective study yielded similar results where E.coli was the most common 
bacteria isolated followed by Staphylococcal microorganisms (Demilie et al., 2012). The major 
contributing factor for isolating higher rates of E.coli is due to urinary stasis in pregnancy which 
facilitates the colonisation of E.coli (Imade et al., 2010). In addition, poor genital hygienic practices by 
pregnant women during their pregnancy could also contribute to the development of infection 
(Schnarr and Smaill, 2008). The likelihood of vaginal E.coli in pregnancy can also occur if the individual 
has a pet that resides in the home. A retrospective study indicated that pets are hosts for both 
pathogenic and non-pathogenic bacteria and women who have pets showed a higher incidence (7%) 
of E.coli colonisation compared to women living without any pets. The increased rate of UTIs 
associated with live-in animals require greater use for oral antibiotics (Einarson, Shuhaiber, and Koren, 
2001; Fluit and Schmitz, 2001; Stokholm et al., 2014; Lee et al., 2020) 
Respiratory tract infections are representative of incidental infections and can lead to acute 
respiratory distress syndrome in pregnancy (Kourtis, Read, and Jamieson, 2014). The estimated 
prevalence of antepartum pneumonia is similar to that of non-pregnant women. Streptococcus 
pneumoniae accounts for 15-20% of all pneumonia cases (Sheffield, 2009). Mycoplasma pneumoniae 
or Legionella are commonly reported causative species (Sheffield, 2009). Pneumonia in pregnancy is 
associated with a higher rate of morbidity and mortality than in non-pregnant women. Furthermore, 
respiratory infections, like TB, also contributes to maternal mortality (Mnyani and McIntyre, 2011). 
The greatest burden of TB infection is in resource poor countries, however, developed countries have 
seen an upsurge in the occurrence of TB over the past few years as a result of immigration. A 
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retrospective study in London, showed an increase in the number of pregnant women with TB, while 
a South African study indicated that 70% of deaths in women were from TB and pneumonia as a result 
of HIV infection (Black, Brooke, and Chersich, 2009). Pregnancy, is not associated with an increased 
risk of TB, but a general increase in the incidence of TB will lead to an increase in TB infection rates in 
pregnant women (Mnyani and McIntyre, 2011). 
Other common infections specific to pregnancy, include breast, perineal, and surgical site infection. 
These sources of infection are visible and more apparent, as it is characterised by localised pain, 
erythema, or discharge (Turner, 2019). These types of infections rarely lead to maternal bacteraemia, 
or sepsis unless they are left untreated. Infections specific to pregnancy are strongly associated with 
a breach in the physical integrity of the skin (Turner, 2019). When such breaches occur, antibiotic 
prophylaxis is the key to avoiding the onset of maternal sepsis (Turner, 2019). 
Improved hygiene and living conditions, the use of antibiotics, and the progression within acute 
hospital care has led to major reductions in critical illnesses or death associated with sepsis (Ford and 
Scholefield, 2014). Despite this, there had been a sudden increase in deaths due to genital tract sepsis, 
particularly from community acquired group A Streptococcal disease, causing several maternal deaths 
in low-income countries (Centre for Maternal and Child Enquiries, 2011). Sepsis is emerging as the 
most common cause of direct maternal death in the United Kingdom (Centre for Maternal and Child 
Enquiries, 2011). A health disparity exists, with up to three times higher maternal death rates in low 
and middle-income countries compared to high-income countries (Bamfo, 2013). 
Previously, there has been a lack of health care guidelines for the management of sepsis in pregnant 
women but with the newly structured care and management plans, the correct diagnosis, and the 
timely treatment of infection in pregnant women will prevent these avoidable maternal deaths (World 
Health Organization, 2017).  
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1.4.2 The modulated immune response in pregnancy 
The immunology of pregnancy has been proven to be considerably complex. Many reviews support 
the idea that the immune system is suppressed which consequently increases the susceptibility of 
bacterial and viral infections influencing the vulnerability of the pregnant population (Mor and 
Cardenas, 2010; Mor, Aldo, and Alvero, 2017). 
The fundamental feature of the immune system is to protect the host from external pathogenic 
invasion through a reinforced network of recognition, communication, trafficking, and repair.  This 
process will depend on the immune system’s ability to recognise the pathogen and co-ordinate cell 
migration to protect the mother and developing foetus (Mor, Aldo, and Alvero, 2017). 
To facilitate implantation, inflammation in the womb occurs which initially alters the state of the 
immune system to tolerate the semi-allogeneic foetus. In a non-pregnant state, the body’s immune 
system would recognise this as a foreign invasion and attack the cells to prevent inflammation, but in 
pregnancy this inflammatory cascade is essential (Mor and Cardenas, 2010; Hewings-Martin, 2017). 
Once implantation occurs, the uterine endometrium is rapidly infiltrated by foetal trophoblast cells 
which develops into the decidua, an immunologically active tissue, anchoring the placenta (Hanna et 
al., 2006; Wells, 2007; Mjosberg, Berg, and Jenmalm, 2010). However, this invasion needs to be 
properly regulated to protect the physical integrity of the uterine wall of the mother (Hanna et al., 
2006). 
Thus, the decidua is constantly changing throughout the pregnancy (Nagamatsu and Schust, 2010).  
Natural killer cells and macrophages are local decidual cells, that are important regulators that 
facilitate tolerance of foetal trophoblasts and adjust to the limitations of their invasion ((Wells, 2007; 
Nagamatsu and Schust, 2010). When placental circulation is established, the peripheral blood also 
comes into close contact with foetal cells, specifically, villous trophoblasts. This may affect the 
peripheral maternal immune response (Hanna et al., 2006). T-cells are also found in the decidua and 
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may play a role in immunoregulation. In addition, dendritic cells that are present may be involved in 
immune-tolerance induction and may impair the clearance of pathogens increasing the disease 
severity (Kourtis, Read, and Jamieson, 2014). 
The presence of immune cells in pregnancy is therefore not associated with a response to ‘foreign 
attack’ but facilitates and protects the pregnancy. The immune system throughout the pregnancy is 
in an altered state that is active, functional, and is carefully controlled resulting in a modulated 
immune response that may increase the risk of infection (Mor and Cardenas, 2010). 
1.4.3 The general approach for antibiotic use in pregnancy 
Pregnant patients require special attention regarding the use of antibiotics. Health care professionals 
must assure that the prescription will be effective, but also safe, as numerous drugs have the ability 
to cross the placenta. There is the challenge of reaching the therapeutic concentration while avoiding 
the risk of adverse drug reactions that may harm the foetus (Leekha, Terrell, and Edson, 2011; Kourtis, 
Read, and Jamieson, 2014). 
The selection of an antibiotic with a safety record is recommended (Norwitz and Greenberg, 2009). It 
is proven that some antibiotics are considered safer to use while others are completely avoided. 
Penicillins, cephalosporins, and macrolides have been used in pregnancy for many years with no 
reported detrimental side effects and are the common classes of antibiotics that are used in pregnant 
women today. Antibiotics such as tetracyclines and fluoroquinolones are contraindicated due to their 
potential for inducing permanent congenital and developmental anomalies (Jalali, 2018). 
Penicillins are the most widely prescribed antibiotic in pregnancy and are considered as the first line 
of treatment when presented with infection. Macrolides and cephalosporins are reserved for patients 
whom are allergic or intolerant to penicillin therapy (Bookstaver et al., 2015). The use of 
aminoglycosides, sulphonamides, nitrofurantoin, and trimethoprim will be dependent on the severity 
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of the infection and the trimester of pregnancy where the benefits surpass the risk (Leekha, Terrell, 
and Edson, 2011).  
The initiation of therapy in the first trimester is generally avoided, as this is the stage where the foetus 
is at the highest risk for developing foetal abnormalities, due to it being the period where foetal 
structural development occurs (Leekha, Terrell, and Edson, 2011). Literature recommends that a 
narrow spectrum antibiotic is more favourable as opposed to a broad-spectrum antibiotic being used 
in pregnancy. It is also crucial that the lowest possible effective dose is used for the shortest duration, 
followed by the prompt replacement of an oral agent in the process of recuperation (Norwitz and 
Greenberg, 2009). 
Therefore, it is essential that antibiotic treatment is only prescribed and initiated when there is 
confirmation of infection followed by obtaining an accurate diagnosis and using an antibiotic that is 
befitting to the needs of the host (Norwitz and Greenberg, 2009). 
1.4.4 Antibiotic safety and the effects associated with prescription antibiotics 
Antibiotic safety is a fundamental concern in pregnancy (Nahum, Uhl, and Kennedy, 2006). Pregnant 
women represent a population where individuality is the epitome of therapy, ensuring that every 
patient is carefully assessed for the possibility of experiencing side effects before being prescribed any 
medication (Nahum, Uhl, and Kennedy, 2006). Antibiotics are widely prescribed in obstetrics and some 
of these drugs have the potential to be embryonically harmful (Amann et al., 2006). 
The effects of an antibiotic may present immediately or could manifest over an extended period -of-
time (Broe et al., 2014; Bookstaver et al., 2015). Maternal anaphylaxis is a common example and is 
characterised as an immediate effect. It may have fatal effects on the foetus, due to compromised 
oxygen levels, exposing the developing new-born to the probable risk of hypoxic-ischaemic 
encephalopathy and permanent central nervous system damage. These effects could result in 
miscarriage, congenital abnormalities, or even neonatal death (de Tejada, 2014).  
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Some of the long-term effects could manifest as a result of the gut microbiota, in both the mother and 
infant being altered. This may potentially interfere with the maturation of the immune system 
influencing childhood advancements and sourcing the risk of low birth weight. Other long-term effects 
may include; childhood asthma, obesity, allergy, atopic dermatitis, autism, diabetes, cerebral palsy, 
and epilepsy (Barros et al., 2010; Ledger and Blaser, 2013; de Tejada, 2014; Rejno et al., 2014; Mueller 
et al., 2015; Anitha et al., 2018; Panduru et al., 2020). Antibiotic administration during pregnancy also 
contributes to alterations in the composition of the commensal vaginal microbiota which effectively 
protects against the proliferation of pathogenic bacteria (Stokholm et al., 2014).  
The physiological changes that occur in the body are known to alter the pharmacokinetic and 
pharmacodynamic properties of the medication, contributing to the risk of medicine use in pregnancy. 
The normal embryonic development, may be affected which could render the antibiotic as a 
dysmorphogenic agent (Amann et al., 2006; Nahum, Uhl, and Kennedy, 2006; Rossiter, 2020). An 
analysis concerning the risk of eleven broad spectrum antibiotics; benzathine penicillin, 
phenoxymethylpenicillin, amoxicillin, chloramphenicol, ciprofloxacin, doxycycline, levofloxacin, 
rifampicin, clindamycin, gentamicin, and vancomycin, was conducted. All eleven antibiotics were able 
to cross the placenta entering the foetal compartment. The concentration for four of these antibiotics 
(ciprofloxacin, clindamycin, levofloxacin, and vancomycin) were of the same enormity or higher in the 
amniotic fluid as compared to in the maternal blood (Nahum, Uhl, and Kennedy, 2006; Menezes, 
Malek, and Keelan, 2011). The pharmacokinetic properties of the medicine and the potential toxicity 
that may result emphasises the level of caution that is required (Anderson, 2005).   
Prior to the obstetric use of antibiotic agents, pregnancy was recognised as a risk factor for severe 
complications but with the use of antibiotics they are now treatable. However, there are still 
important therapeutic implications that must be considered for both the developing foetus and 
mother when using these drugs (Kourtis, Read, and Jamieson, 2014). There is currently inadequate 
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data available for medicines that can be used in pregnant women making it a challenge to consider 
any antibiotic as ‘’safe’’ (Bookstaver et al., 2015; Jalali, 2018).  
1.4.5 The effect of the physiological changes in pregnancy on the pharmacokinetic and 
pharmacodynamic properties of the drug 
Pregnancy is a physiological state which encompasses hormonal and anatomical changes (Augustine, 
Ladyman, and Grattan, 2008). This places significant biological demands on a woman. To cope with 
these immense demands, the hormones of pregnancy are released to allow the body to adapt to the 
various maternal physiological functions (Costantine, 2014). These adaptations that occur within the 
major organ systems in the body, subsequently affect the pharmacokinetic and pharmacodynamic 
properties of the drug (Costantine, 2014; Stock and Norman, 2019).  
The upsurge in the secretion of progesterone and oestrogen, is vital for the body in an effort to support 
the requirements and maturation of the foetus. This rise leads to delayed gastric emptying and 
prolonged transit time, intensifying gastric pressure within the bowel (Liu et al., 2002). The absorption 
of the active constituent may be profoundly affected by the gastrointestinal system. Delayed gastric 
emptying is a major factor correlated to the oral bioavailability of the drug. The time taken to reach 
the peak concentration (Tmax) of the drug is increased, thereby, lowering the maximum 
concentrations (Cmax), thus hindering the oral bioavailability of the drug. The incidence of nausea and 
vomiting in pregnancy may also lower drug plasma levels. Additionally, as a consequence of these 
elevated sex hormones, drug metabolism is altered. The drug metabolising enzymes including those 
involved in phase I (reduction, oxidation, or hydrolysis) or phase II  metabolism (glucuronidation, 
acetylation, methylation, and sulphation) undergo changes (Zhou and Ma, 2018). The alkalisation of 
the gastric pH may also increase ionisation of weak acids, reducing the absorption of drugs (Liu et al., 
2002).  
The heart also plays a major role in the pharmacodynamic alterations. The myocardial contractility, 
cardiac compliance, and the ventricular wall mass increases. These changes increase both the heart 
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rate and stroke volume resulting in a higher maternal cardiac output (Pacheco, Costantine, and 
Hankins, 2013). The uterine blood flow also increases as a result, although the exact origin of the 
increased blood volume is not fully understood. The mechanism may be through nitric oxide mediated 
vasodilatation, increased arginine vasopressin production, and mineralocorticoid activity 
accompanied by water and sodium retention, leading to hypervolemia (Carbillon, Uzan, and Uzan, 
2000). The pregnancy induced hypervolemia is thought to provide a survival advantage, however, the 
increase in blood, water, and plasma volume including capillary hydrostatic pressure, increases the 
volume of distribution of various drugs within the body. This fluctuation in volume require higher 
dosages of the antibiotic particularly if the drug is composed of a hydrophilic integrant (Carbillon, 
Uzan, and Uzan, 2000).  
In addition, the kidney is one of the main sources responsible for elimination affecting drug disposition 
and influencing the drugs bioavailability. In pregnancy, the glomerular filtration rate in the kidney is 
accelerated affecting the elimination of renally excreted substrates resulting in a shorter half-life. 
Ampicillin, cefuroxime, cefazolin, and piperacillin are the common antibiotics that are renally excreted 
(Anderson, 2005).   
Lastly, the transplacental diffusional capacity of the foeto-maternal membrane increases as it begins 
to mature and thin throughout the different gestational stages. This results in drug concentrations 
being 10-15% lower in the latter stages of pregnancy requiring the need for higher dosages 
(Costantine, 2014; Zhou and Ma, 2018). The descending albumin levels lead to reduced protein 
binding displaying higher concentrations of the unbound drug, thus increasing the bioactivity of drugs 
that may be protein bound (Costantine, 2014).  
The physiological metamorphoses that pregnancy induces has significant pharmacodynamic and 
pharmacokinetic effects on the use of antibiotics. These modifications occur throughout the major 
anatomical structures to support the growth of the foetus make it challenging to treat infections in 
pregnant women where the strength, dose, dosing interval, and duration of the drug has to be 
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carefully tailored to needs of the individual  (Bookstaver et al., 2015). Research indicates that firm data 
on pharmacokinetics as well as efficacy and the optimal use of medicines are still extremely limited, 
but recommendations can be made using existing information (Stock and Norman, 2019).   
1.4.6 The Pregnancy and Lactation Labelling Rule (PLLR) 
The Food and Drug Administration (FDA) plays an important role in advocating the safety of medicines 
in pregnant women. Prescribing during pregnancy and lactation involve complex maternal and foetal 
risk–benefit considerations. The primary objective of the FDA is to provide detailed prescribing 
information in a manner that is clear and useful to clinicians when prescribing (Feibus, 2008).  
The FDA previously classified drugs according to categories (A, B, C, D, and X), as shown in Table 2.  
However, this classification system did not allow for the adoption of new information and did not 
accurately communicate the degree of foetal risk. It was determined that the FDA categories were not 
helpful in assisting health care providers to effectively balance the risk and benefit of the drug, 
resulting in poor clinical decisions (Food and Drug Administration, 2017; Food and Drug 
Administration, 2019).  
Table 2 The FDA assigned pregnancy categories (Food and Drug Administration, 2017) 
Category A Adequate and well-controlled studies in pregnant women 
have not shown an increased risk of foetal abnormalities. 
Category B Animal studies have revealed no evidence of harm to the 
foetus. However, there are no adequate and well-
controlled studies in pregnant women that have shown 
adverse effects or alternatively, adequate and well-
controlled studies in pregnant women have failed to 
demonstrate a risk to the foetus. 
Category C No animal studies have been conducted or animal studies 
have shown an adverse effect. However, there are no 
adequate and well-controlled studies in pregnant women. 
Category D Adequate and well controlled studies in animals or 
pregnant women have demonstrated positive evidence of 
foetal abnormalities. However, the benefits of therapy may 
outweigh the potential risk. 
Category X Adequate and well-controlled studies in animals or 
pregnant women have demonstrated positive evidence of 
foetal abnormalities. The use of this product is 
contraindicated in women who are or may become 
pregnant.  
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The Pregnancy and Lactation Labelling Rule (PLLR) has recently been implemented and will replace 
the FDA categories (Food and Drug Administration, 2019). This regulation will be implemented for new 
drugs that are being registered and will subsequently be phased in for older drugs over a period of 
time. The new pregnancy rule consists of three categories: pregnancy exposure registry, risk summary, 
and clinical considerations (Pernia and Demaagd, 2016). The PLLR will provide a narrative summary of 
the risks of a drug during pregnancy. In addition, it will provide supporting data that is required in 
labelling to provide more reliable information for clinicians. Information will be based on; human and 
animal studies, post marketing surveillance, pharmacokinetic properties, and time and duration of 
exposure (Food and Drug Administration, 2019). 
The PLLR allows for clinicians to make decisions based on a wider array of information. The 
implementation of this new regulation will be a step forward in optimising drug usage in pregnant 
women (Food and Drug Administration, 2019).  
1.4.7 The implications of antibiotic resistance in pregnant women 
The discovery of antibiotics is known as one of the greatest advances that fortify modern medicine by 
progressively increasing life expectancy. However, the complacent use of these novel drugs over the 
last few decades has introduced a global health crisis. The clinical misuse of antibiotics is a major 
determinant, catalysing the emergence of drug resistance consequently affecting all population 
groups (Haak and Radyowijati, 2003; Leekha, Terrell, and Edson, 2011; Blair et al., 2015).  
In 2014, the World Health Assembly expressed serious apprehension regarding antibiotic resistance 
due to the peril of inappropriate antibiotic use (de Tejada, 2014). The extensive use of antibiotics in 
the community and in hospitals contribute to this epidemic. Majority of studies proved that 25-68% 
of antibiotic prescriptions in a hospital setting were deemed sub-optimal (Charani, Cooke, and Holmes, 
2010). 
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Bacterial organisms have become intrinsically resistant to antibiotics via the exchange of genetic 
material and chromosomal mutations resulting in the emergence of multi-drug resistant bacteria 
commonly known as superbugs (Davies and Davies, 2010). The various classes of Streptococcus, 
Staphylococci, Enterobacteriaceae, and Pseudomonas are considered as the main causative agents in 
respiratory, urinary, and cutaneous infections. These bacteria are now resistant to practically all of the 
long-established classes of antibiotics (Davies and Davies, 2010). It is projected that two million people 
are infected with antibiotic resistant bacteria annually, with 23 thousand deaths occurring in the 
United States and 25 thousand deaths occurring in Europe, both, as a result of multi-drug resistant 
bacterial infections (Blair et al., 2015). 
The contributing factors of antibiotic resistance are multi-plex and involve different rationale ensuing 
its use (Haak and Radyowijati, 2003). Firstly, the misdiagnosis and injudicious prescribing etiquette of 
antibiotics by health care professionals, especially for viral acquired infections, greatly influence the 
inactivation of the molecular mechanism of the drug, simultaneously affecting the rate of resistance. 
A study conducted in the United States indicated that antibiotic use is unnecessary in almost half of 
the patients that receive treatment (Charani, Cooke, and Holmes, 2010; Leekha, Terrell, and Edson, 
2011; Barlam et al., 2016). Prolonged prophylaxis and the practice of empiric antibiotic therapy when 
there is no evidence of positive cultures or the continuation of therapy when the patient shows no 
response were confirmed as the most common errors resulting in resistance (de Tejada, 2014). In 
addition, the lack of basic knowledge, focusing only on the benefits of antibiotics with little concern 
for long-term consequences together with the use of poorly designed guidelines contribute to these 
imprudent decisions (Mulder et al., 2018). 
During the last decade, resistance to penicillins, macrolides, and cephalosporins have increased 
significantly (Barlam et al., 2016). Pregnant women have used these antibiotics for years with no 
reported detrimental effects, but they are gradually becoming less effective requiring the use of 
broader spectrum antibiotics where safety has not been established (Walsh and Wright, 2005). A study 
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conducted in Bangladesh expressed the growing concern of antibiotic resistance among participants 
as gram-negative uro-pathogens were highly resistant to ampicillin, azithromycin, and second and 
third generation cephalosporins. Studies conducted in South-East Asia, reported that 16-68% of E.coli 
isolates and 34–81% of Klebsiella isolates were resistant to third generation cephalosporins (Lee et al., 
2019). 
Antibiotics are revolutionary drugs. The study of microbiology, antibiotic consumption, and the 
emergence of resistance are the fundamental principles of antibiotic stewardship that need to be 
understood in order to implement strategies using a multi-faceted approach, especially in developing 
countries  (Charani, Cooke, and Holmes, 2010). 
1.5 The influence of health behaviour and the perception of risk on drug therapy 
The understanding of beliefs, awareness, knowledge, and perception of medicines are vital to attain 
optimal drug therapy. These are significant factors that influences the success of medicine use in any 
population. Thus, the understanding of perception offers an opportunity to contribute to the provision 
of optimised health care (Ssemaluulu and Adome, 2006; Alomi et al., 2018). 
The Health Beliefs Model (HBM) provides a conceptual framework to assist in the understanding of 
health behaviour and perception (Glanz and Bishop, 2010). This model has been successfully adapted 
to fit diverse, multi-cultural, and contemporary contexts (Griffin, 2011; Scarinci, Bandura, and Hidalgo, 
2012). It provides five paradigms that predict health behaviour; risk susceptibility, risk severity, 
benefits, barriers to action, and cues to action (Champion and Skinner, 2008). The model may assist 
health care providers in achieving the desired drug therapy response.   
The perceived risk of medicine use is a key aspect that affects health behaviour and may contribute 
to unrealistic beliefs (Mulder et al., 2018). The knowledge of medicine use is important in preventing 
drug-related problems such as; non-adherence or termination of therapy, especially when the benefits 
of drug therapy supersedes the risk (Zaki and Albarraq, 2014). In addition, the insufficient provision of 
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medicine information could be an alternative explanation for the unwillingness to use necessary 
medicines that are regarded as safe in pregnancy (Widnes, Schjott, and Granas, 2012).  
Studies have revealed that the perception women have regarding any medication is generally over-
estimated in comparison to the actual risk profile of the medicine (Widnes et al., 2013; Mitchell and 
McClean, 2014). Women source information from health care professionals, Patient Information 
Leaflets (PILs), family, friends, and the internet (Mulder et al., 2018). Some of these sources may 
contribute to the unrealistic perception of risk (Nordeng, Ystrom, and Einarson, 2010; Mulder et al., 
2018).  
The perception of the patient may also vary depending on various socio-economic predictors such as; 
level of health literacy, age, level of education, parity, geographical region, and most importantly their 
beliefs and opinions that affect their ability to make well informed health decisions (Widnes and 
Schjott, 2017).   
There are numerous aspects that are pertinent to address when approaching the issue of realistic risk 
perceptions. To assess and provide realistic risk estimates, both pregnant women and physicians need 
access to factual sources of information enabling confidence in appropriate drug use and prescribing 
(Nordeng, Ystrom, and Einarson, 2010). Furthermore, the provision of advice and information by 
physicians and pharmacists can positively or negatively affect a patient’s perception. Positively-
framed advice, therefore, may allow for the evaluation of the medicines beneficial uses rather than 
focusing on the possibility of harm  (Mulder et al., 2018). 
The understanding of risk perception, particularly among pregnant women may assist in providing 
interventions in their health behaviour, ensure adherence, and promote awareness of medicines 
among this population (Alomi et al., 2018).   
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Chapter Summary 
This chapter highlighted the prevalence of infection, the implications of antibiotic use, and its safety 
in pregnant women. The chapter also focused on health behaviour and its impact on the use of 
antibiotics.   
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Chapter 3: Manuscript I 
Introduction 
Chapter three describes the use of antibiotics among pregnant women in a public sector hospital. The 
study quantifies antibiotic usage and comments on the trend, rationale, and safety profile of those 
antibiotics.  
The chapter is presented in manuscript format in accordance with the College of Health Sciences 
guidelines for dissertation submission at the University of KwaZulu-Natal (UKZN).  
The manuscript has been submitted for publication to the journal: Health SA Gesondheid (see 
Annexure 4). This chapter has been written, formatted, cited, and referenced according to the 
journal’s submission guidelines. The journal instructions to the author can be viewed in Annexure 5.  
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Abstract 
Background  
Most pregnant women are exposed to medication during pregnancy. Antibiotics are among the more 
frequently prescribed medicines in pregnant women and the use of antibiotics are increasing. 
However, with limited studies available in this population, the safe use of antibiotics in pregnancy 
remain a concern.  
Aim 
This study aims to quantify the use of antibiotics among pregnant women and comment on the 
rationale and safety profile of those prescribed.  
Setting  
A tertiary and quaternary public hospital located in Durban, KwaZulu-Natal.  
 Methods 
Demographic and treatment information of women were collected retrospectively from January 2019 
to July 2019. A total of 184 pregnant patients, having received antibiotic therapy, were included in the 
study. Data were obtained from an electronic database and were recorded using Excel®. Descriptive 
and analytical measures were used to analyse both patient demographics and treatment variables.  
Results 
A total of 416 antibiotic prescriptions, issued to 184 patients, were reviewed. Penicillins (39.7%), 
macrolides (13.0%), and combination penicillin-and-beta-lactam inhibitors (12.3%) were reported as 
the most prescribed antibiotics. Rifamycin (2.9%), hydrazides (2.2%), and aminoglycosides (1.9%) were 
less frequently prescribed. Most antibiotics were prescribed for diseases of the circulatory system 
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(36.1%). A significant correlation was found between the duration of therapy and the age of the 
patient (>20, p=0.0009, 20-29, p=0.017, 30-42, p=0.03). 
Conclusion 
Several classes of antibiotics are used in pregnancy despite the lack of available safety data and clinical 
evidence. Informing women of the potential side effects and keeping abreast with new information 
plays an important role in the safe, rational, and effective use of medicines that contribute to 
improving maternal health.  
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Introduction 
Antibiotic use in pregnancy is increasing and antibiotics account for a significant percentage of all 
medication that is prescribed in pregnancy (Broe et al., 2014; Kuperman and Koren, 2016). According 
to a European study, one out of every four pregnant women is prescribed an antibiotic (Santos, 2010; 
Stokholm et al., 2013; Bookstaver et al., 2015).  
The use of antibiotics in pregnancy is attributed to the fact that pregnancy predisposes the body to 
infection. Hormone fluctuations and changes in immunity are the primary causes for increasing the 
body’s susceptibility to infection (Cherney, 2016). Genitourinary infections are the most frequently 
occurring illness contributing to the upsurge in antibiotic use (Lee et al., 2019, 2020). According to a 
recent study, 72% of antibiotic treatment is a result of vaginal candidiasis, urinary, and respiratory 
tract infections (Amann et al., 2006). 
Antibiotic safety is an essential factor when considering its use in pregnancy. Antibiotics may be 
teratogenic and may have both short- or long-term effects on the foetus (Vidal et al., 2013). Several 
modifying influences may affect the severity of teratogenicity. These include; the gestational period 
of the pregnancy, the dose and duration of therapy, genetic predisposition, environmental factors, 
and the degree of drug transfer across the placenta (Amann et al., 2006; Nahum, Uhl, and Kennedy, 
2006; Ledger and Blaser, 2013; Rossiter, 2020).   
There remains a degree of inadequate evidence regarding the safety of antibiotics used in pregnancy 
due to ethical limitations (Bookstaver et al., 2015). Clinical trials among the pregnant population are 
restricted, hence the teratogenicity of various medicines are unknown (Crider et al., 2009). A review 
regarding antibiotic use stated that approximately only ten percent of medicines used in pregnancy 
are supported by safety data (Adam, Polifka, and Friedman, 2011).  
The primary aim of this study was to evaluate the use of antibiotics among pregnant women attending 
a public health care facility. The main objective of the study was to quantify the types of antibiotics 
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used in pregnant women. The secondary objectives were to comment on the trends, rationale, and 
safety profile of the prescribed antibiotics. While the Pregnancy and Lactation Labelling Rule (PLLR) 
has come into effect for all new drugs registered in the United States and is being phased in for older 
drugs, medication use in this study was classed according to the “A to X” categories of the Food and 
Drug Administration (FDA) (Feibus, 2008; Food and Drug Administration, 2017; Food and Drug 
Administration, 2019).  
Research methods and design 
Study design and setting 
This retrospective study was conducted over seven months (January 2019 to July 2019) at a tertiary 
and quaternary public hospital, centrally located in Durban, KwaZulu-Natal (Department of Health, 
2017). 
Study population and sampling strategy 
The selected population consisted of both in-patients and out-patients. Participants included in the 
study met the following eligibility criteria:  
• 18 years of age or above. 
• Female and pregnant. 
• Treated with an antibiotic as an inpatient or outpatient. 
Details around antibiotic use, diagnosis, patient demographic information, and HIV status were 
recorded. 
A total of 184 patients met the inclusion criteria. This sample size was large enough to allow for a 
detailed analysis of antibiotic usage as each patient received an average of two to three prescriptions, 
yielding a total of 416 prescriptions.  
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Data collection 
Data was obtained from a software programme called MediTech®. MediTech® electronically stores 
patient files and treatment information. A pre-designed data collection tool was used to record 
available demographic and treatment information from patient files (Appendix 1). The template was 
developed according to guidelines by the World Health Organisation (WHO) that included key 
antimicrobial use indicators designed specifically for the collection of data in hospitals (USAID, 2012). 
Data on the following elements were recorded: 
• Demographics (age, ethnicity, risk of pregnancy, and HIV status). 
• Antibiotic name. 
• Dose. 
• Route of administration. 
• Frequency of administration. 
• Duration of treatment. 
All information collected were kept confidential. Patient names were coded and records were kept in 
a password protected device. Individual patients’ written informed consent for the collection of data 
were not needed, as only anonymised, retrospective data were extracted. 
Data analysis  
Descriptive and analytical measures were used to describe both patient demographics and treatment 
variables. Measures of central tendency such as the frequency, mean, and median were calculated. 
Antibiotic usage patterns among the participants were then identified. The quantitative data values 
are represented in frequency distribution tables by grouping them into categories as well as in a 
frequency distribution bar chart. The linear relationship between the patient demographics and 
treatment variables were established using correlation analysis. The relationship between duration, 
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age, HIV co-infection, and the number of prescriptions were investigated using the Chi-square test. 
The level of significance was set at α=0.05. 
The results were classified using the FDA safety categories as follows: Category B are drugs where 
animal studies may or may not have revealed evidence of harm to the foetus; however, there are no 
adequate and well-controlled studies in pregnant women. Category C are drugs where animal studies 
may or may not have been conducted to show adverse effects, but there are no adequate and well-
controlled studies in pregnant women. Category D are drugs where adequate, well-controlled studies 
in animals or pregnant women have demonstrated positive evidence of foetal abnormalities. 
However, the benefits of therapy may outweigh the potential risk (Food and Drug Administration, 
2019). 
Eliminating Bias 
The probability for biased selection was eliminated as a probability sampling method was adopted 
which included every participant who visited the hospital from January to July 2019. Secondly, data 
were collected using a pre-designed tool and the extraction of data were not performed by medical 
staff who prescribed or dispensed the antibiotics.  
Ethical approval 
Ethical approval was sought from the relevant bodies; the Biomedical Research and Ethics 
Committee (BREC) located at the University of KwaZulu-Natal (UKZN) (Annexure 1), KZN Department 
of Health (KZN-DoH) (Annexure 2), and the Head of Department and Chief Executive Officer (CEO) at 
the study site (Annexure 3).  
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Results  
Demographic and general characteristics 
Patient demographic data for 184 pregnant women are shown in Table 1. Less than 10% of the study 
population were between the age of 18-20. The majority of women were evenly distributed between 
the other two remaining age groups (20-29, 30-42). Almost 92% of the study population were Black 
African women, with a small percentage being Asian women (4.9%), White women (1.6%), and women 
of Mixed-race (1.1%). Many of the women (82.1%) were reportedly single, 12% being married while 
the marital status of the remaining women (6.0%) were not reported. A significant percentage (63.1%) 
of women were in their third trimester of pregnancy, with less than 35% of pregnancies being 
categorised as high risk. A large percentage of women (45.7%) who were included in the study were 
co-infected with HIV. Most women visited this tertiary facility between two to five times during their 
pregnancy.  
Correlations investigated 
Demographic variables correlated with the duration of antibiotic treatment, included:  
• Age group (>20, p=0.0009, 20-29, p=0.017, 30-42, p=0.03). 
• Gestational week (p=0.4). 
• HIV co-infection (p=0.9). 
• High-risk pregnancy (p=0.9). 
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Table 1 Characteristic and demographic data of participants, n=184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics  Frequency 
N 
% 
Age 
18>20 
20-29 
30-42 
 
14 
86 
84 
 
7.6 
46.7 
45.7 
Race 
Black 
Asian 
White 
Mixed-race 
Other  
 
169 
9 
3 
2 
1 
 
91.8 
4.9 
1.6 
1.1 
0.5 
Marital status 
Married 
Single 
Not reported 
 
22 
151 
11 
 
12 
82.1 
6.0 
Gestational weeks  
  0-13  
14-26 
27-40 
Not reported 
 
0 
3 
116 
65 
 
0 
1.6 
63.0 
35.3 
 
High-risk pregnancy  
Yes  
No  
 
 
63 
121 
 
34.2 
65.8 
HIV Co-infection 
Yes 
No  
 
84 
100 
 
45.7 
54.3 
Inpatient days 
<3  
4-14 
18-88 
 
46 
88 
50 
 
25.0 
47.8 
27.2 
 
Outpatient visits 
<=1 
2-5 
5-15 
 
57 
84 
43 
 
31.0 
45.7 
23.4 
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Quantifying antibiotic usage in pregnancy  
A description of the different antibiotic classes and their prescribed frequencies are shown in Table 2. 
A total of 416 prescriptions were dispensed to 184 patients, with each woman receiving more than 
one course of antibiotic therapy during their pregnancy. Most women received an average of one to 
two prescriptions, with 8.7% of patients receiving more than four prescriptions during their 
pregnancy. A large percentage (88.9%) of prescriptions were FDA category B antibiotics with the 
remaining 11.1% being category C and D. Penicillins were the most frequent class (39.7%) of antibiotics 
prescribed to pregnant women followed by macrolides (13.0%) and combination penicillin- and- beta-
lactam inhibitors (12.3%). The use of nitrofurantoin (8.1%) and carbapenems (6.3%) were also among 
the commonly used antibiotics, although they were slightly less prescribed in comparison to 
macrolides and beta-lactams. Other antibiotics such as rifamycin, hydrazides, aminoglycosides, 
fluoroquinolones, and trimethoprim-sulphonamide combinations were sparingly prescribed.  
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Table 2 Frequencies of the prescribed antibiotic classes and the respective FDA categories, n=184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FDA categories Antibiotic class Frequency 
 
% 
B Combination of 
penicillin and 
beta-lactam 
inhibitors 
 
Carbapenems 
(except 
imipenem-
category C) 
 
Glycopeptides 
 
Imidazoles 
 
Lincosamides 
 
Macrolides 
 
Nitrofurantoin 
 
Penicillins 
 
Third generation 
cephalosporins 
 
Topical 
antibiotics 
 
Total  
51 
 
 
 
 
26 
 
 
 
 
3 
 
20 
 
3 
 
54 
 
34 
 
165 
 
13 
 
 
1 
 
 
370 
12.3 
 
 
 
 
6.3 
 
 
 
 
0.7 
 
4.8 
 
0.7 
 
13.0 
 
8.1 
 
39.7 
 
3.1 
 
 
0.2 
 
 
88.9 
C Amphenicols 
 
Fluoroquinolones 
 
Hydrazides 
 
Polymyxins 
 
Rifamycins 
 
Trimethoprim - 
sulphonamide  
combinations 
 
Total 
3 
 
5 
 
9 
 
2 
 
12 
 
7 
 
 
 
38 
0.7 
 
1.2 
 
2.2 
 
0.5 
 
2.9 
 
1.7 
 
 
 
9.2 
D Aminoglycosides 
(except 
gentamycin- 
category C) 
 
Total 
8 
 
 
 
 
8 
1.9 
 
 
 
 
1.9 
  
Total 
 
416 
 
100 
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Category B antibiotics commonly prescribed 
The five most frequently prescribed category B antibiotic classes and their respective dosing 
characteristics, including the route of administration and indication, are described in Table 3. 
Phenoxymethylpenicillin (pen V) was the most prescribed penicillin antibiotic (74.5%). Among the 
combination penicillins, amoxicillin-clavulanic acid was commonly used (21.8%). Azithromycin was the 
only prescribed macrolide and meropenem was one of the frequently prescribed carbapenems.  
The strength, dosing frequency, and average duration varied among the different classes with most 
women receiving an oral or intravenous (IV) dose of administration, while few received treatment 
intramuscularly (IM). Most antibiotics were given for seven days or less. Phenoxymethylpenicillin was 
an exception as the average duration for this antibiotic was nine days. The remaining penicillin classes, 
nitrofurantoin, and carbapenems were commonly used for four to seven days. Macrolides were 
frequently prescribed for less than or equal to three days.  
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Table 3 Characteristics of frequently prescribed FDA category B antibiotic classes 
 
 
 
 
 
 
1 Intramuscular  
2 Pen V - Phenoxymethylpenicillin 
3 Intravenous 
Antibiotic class Description Strength 
(mg) 
Dosing 
frequency 
Average 
duration 
(Days) 
Route of 
administration 
Common 
indication by 
disease category 
No of 
prescriptions 
Penicillins Amoxicillin 500, 1000 
 
8 Hourly 4 Oral 
IM1 
Diseases of the 
circulatory system 
24 
Flucloxacillin 250-500 6 Hourly 6 Oral 8 
Pen V2 125, 250 12 Hourly 9 Oral 123 
Ampicillin 1000 8 Hourly 4 IV3 1 
Benzathine 
benzyl-penicillin 
2400 Once-daily 1 IM 9 
 
 
Total       165 
Macrolides Azithromycin 250, 500, 
1000 
Once-daily 3 IV 
Oral 
Diseases of the 
circulatory system 
54 
Total       54 
Combination of 
penicillins and beta-
lactam inhibitors 
 
Amoxicillin/ 
clavulanic acid 
375 
1000 
 
1200 
8 Hourly 
12 Hourly 
 
8 Hourly 
4 Oral 
IV 
 
 
Diseases of the 
circulatory system 
36 
Piperacillin/ 
tazobactam 
2250 
 
4500 
8 Hourly 
 
 
3 IV 15 
 
 
 
Total       51 
Nitrofurantoin Nitrofurantoin 50 
100 
6 Hourly 5 Oral Diseases of the 
genitourinary 
system 
34 
Total       34 
Beta-lactam 
carbapenems 
Imipenem/ 
cilastatin 
500, 1000 6-8 Hourly 4 IV Diseases of the 
genitourinary 
system 
5 
Meropenem 500, 1000 6-8 Hourly 3 21 
Total       26 
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Category C and D antibiotics commonly prescribed 
Table 4 indicates the prescribed category C and D antibiotics with their subsequent characteristics. 
Rifamycins (2.9%), hydrazides (2.2%), and aminoglycosides (1.9%) were the three most prescribed 
category C and D drug classes. Amikacin was used more often in comparison to gentamicin. 
Quinolones were prescribed to five patients. Chloramphenicol, as a topical antibiotic, was prescribed 
to three patients. Colistin was used in two patients.  
More than 67% of the antimycobacterial agents (rifamycins and hydrazides) were dispensed for 
periods longer than eight days. Half the women who were treated with aminoglycosides received the 
drug for three days or less, while the other half received it for four to seven days. Fluoroquinolones 
were mostly prescribed for a short period of fewer than five days. Trimethoprim-sulphonamide 
combinations were dispensed to seven patients, with most patients receiving treatment for 
approximately 20 days. 
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Table 4 Characteristics of frequently prescribed FDA category C and D antibiotic classes 
 
 
 
 
 
 
Antibiotic class Description Strength 
and 
dosing 
frequency 
(mg) 
Dosing 
frequency 
Average 
duration 
(Days) 
Route of 
administration 
Common indication 
by disease category 
 
No. of 
prescriptions 
Rifamycins Rifampicin 450-600 Daily 7 Oral Diseases of the 
respiratory system 
12 
Total       12 
Hydrazides Isoniazid 100-300 Daily 23 Oral Diseases of the 
respiratory system 
9 
Total       9 
Aminoglycosides Amikacin 250, 500, 
900, 1000 
Once-
daily 
3 
 
3 
IV Diseases of the 
genitourinary 
system 
7 
Gentamicin 240 1 
Total       8 
Trimethoprim - 
sulphonamide 
combinations 
 
Co-trimoxazole 160/800 
 
320/1600 
12 Hourly 
 
6 Hourly 
22 Oral Diseases of the 
genitourinary 
system 
7 
Total       7 
Fluoroquinolones Ciprofloxacin 
 
 
 
500 
 
12 Hourly 5 Oral 
IV 
Diseases of the 
circulatory system 
5 
Total       5 
Amphenicols Chloramphenicol  12 Hourly 28 Topical Diseases of the skin 
and tissue 
3 
Total       3 
Polymyxins Colistimethate 
(Colistin) 
80 
 
160 
12 Hourly 
 
8 Hourly 
8 IV Other specified 
diseases 
complicating 
pregnancy and 
childbirth that were 
not mentioned 
 
2 
 
 
 
 
 
Total       2 
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Disease Categories 
Figure 1 shows the percentage of prescriptions that were dispensed for the main categories of 
infections. Majority of prescriptions were for infections of the blood and circulatory system (36.1%), 
followed by other specified infections (29.9%), and genitourinary infections (13.2%). Endocrine and 
metabolic infections (6.7%) and infections of the nervous system (5.5%) contributed to a smaller 
number of prescriptions.  
 
Figure 1 The percentage of prescriptions allocated to each disease category 
Discussion 
This study aimed to evaluate the trends in antibiotic use among pregnant women and to comment on 
their rationale and safety profile. 
A significant correlation was established between the age of a patient and the duration of the 
antibiotic course. As the age increased, the duration of therapy increased (>20, p=0.0009, 20-29, 
p=0.017, 30-42, p=0.03). No previous studies have investigated this relationship. It is possible that with 
age, the difference in hormone levels and changes in the patients’ immune response may contribute 
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to a longer recovery, hence the longer duration of treatment. However, this may differ among 
individuals and various studies (Erickson and Banks, 2019). This explanation, therefore, cannot be 
generalised.  
The prevalence of the human immunodeficiency virus (HIV) in South Africa remains high and 
considering the large percentage of HIV-positive women in this study, it was expected that the 
duration of antibiotic therapy and the number of prescriptions dispensed to these women would be 
higher compared to HIV-negative pregnant women (Cohn and Clark, 2014; Ntlantsana, 2019). There 
was, however, no significant correlation between HIV status and antibiotic use or treatment duration 
(p=0.9). This might be an indication of the positive impact of antiretroviral (ARV) therapy decreasing 
the possible risk of infection in HIV-positive individuals; similarly, these results were found in KwaZulu-
Natal and Nigeria, although this explanation cannot be extrapolated to the general population and is 
limited to this study (Mepham et al., 2011; Ntlantsana, 2019; Calder, Hara, and Tabatabai, 2020).  
The gestational period is an important factor that influences antibiotic therapy. Multiple studies advise 
against the use of drugs in the first trimester as the foetus is still developing (Knothe and Dette, 1986; 
Shaaban et al., 2020). In our study, no patients were treated with an antibiotic in their first trimester 
of pregnancy. The majority of patients received treatment in their third trimester, with only a few 
women receiving treatment in their second trimester. A recent Cochrane review evaluated the use of 
antibiotics in the second and third trimester. The review established that there was no increased risk 
of congenital abnormality between the two trimesters. However, the authors concluded that there 
was insufficient evidence to fully evaluate possible foetal harm (Thinkhamrop et al., 2015). 
As to be expected, almost two-thirds of the study population received a beta-lactamase sensitive 
agent with phenoxymethylpenicillin, used most commonly. These antibiotics remain widely prescribed 
in pregnancy (Heikkilä and Erkkola, 1994; Bookstaver et al., 2015). Current literature indicates the high 
use of beta-lactams, especially penicillins in pregnant women, due to its longstanding safety record. 
Literature indicates that beta-lactams represent approximately 65% of all antibiotic treatment used 
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during pregnancy, with penicillins accounting for 30% (Heikkilä and Erkkola, 1994; Bookstaver et al., 
2015). Similar results were obtained from our study, indicating that 61% of all antibiotics prescribed 
to pregnant women belonged to a beta-lactam class. We, however, found a slightly higher percentage 
(39.7%) of women being treated with penicillin in comparison to this northern European study. The 
results from our study are therefore consistent with the current trends of antibiotic therapy in 
pregnancy (Anitha et al., 2018).  
Our study found that the duration for penicillins ranged from one to nine days and was typically within 
the normal prescribing guidelines. However, the hydrophilic nature of these compounds makes them 
more water-soluble; hence, the potential for lower serum concentrations, due to a more rapid renal 
clearance. Observational studies have also documented these changes resulting in lower 
concentrations especially in the third trimester (Frederiksen, 2001; Anderson, 2005). These changes 
may lead to pharmacokinetic alterations that require dose adjustments or careful monitoring and 
assessment (Costantine, 2014). Dose adjustments in this study were not evident.  
As resistance to commonly used drugs increases, the use of other antibiotic classes will need to be 
sought where the safety profile has not yet been established presenting as a challenge (Walsh and 
Wright, 2005; Lamont, Blogg, and Lamont, 2014). Empiric antibiotic prescribing due to financial and 
practical implications also contribute to the crisis of antibiotic resistance. In this study, the impact of 
bacterial resistance was already apparent in that some women could not be administered first-line 
agents (penicillin monotherapy) but were placed on combination penicillins, cephalosporins, and 
carbapenems. Observantly, combination penicillins-and-beta-lactam inhibitors, were used in 12% of 
patients. Additionally, two patients were administered colistin, a drug that is not registered in South 
Africa and reserved for highly resistant patients (Mendelson et al., 2018).  
Azithromycin, a sub-class macrolide, and nitrofurantoin were also among the commonly prescribed 
antibiotics. Macrolide prescribing during pregnancy is not uncommon as similar results have been 
reported elsewhere for both macrolides and nitrofurantoin (Ramsey et al., 2003; Sarkar et al., 2006; 
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Dinur et al., 2013; Fan et al., 2020). The use of macrolides in pregnancy is however a growing concern 
(Fan et al., 2020). Significantly, a recent study by Fan et al. followed children from birth to 14 years of 
age (Fan et al., 2020). It was concluded that macrolide prescribing in any trimester was associated 
with an increased risk of genital malformation whereas a previous cohort of 1033 women exposed to 
macrolides (erythromycin, azithromycin, clarithromycin, or roxithromycin), reported that there were 
no association with this drug and the development of major abnormalities in the foetus (Dinur et al., 
2013; Fan et al., 2020).  
Nitrofurantoin, an antibiotic specific for the urinary system, was used in this study. Some studies 
reported no severe malformation during pregnancy while others found conflicting evidence. A meta-
analysis consisting of eight studies did not demonstrate any link between nitrofurantoin exposure in 
women and major congenital malformation. However, other studies indicated that nitrofurantoin 
might increase the risk of haemolytic anaemia in pregnant patients with severe glucose-6-phosphate 
dehydrogenase deficiency (Crider et al., 2009; van de Mheen et al., 2014). The National Birth Defects 
Prevention Study (NBDPS) found a significant association between nitrofurantoin use during 
pregnancy and cleft lip and palate (Crider et al., 2009). These adverse effects have not been commonly 
reported and nitrofurantoin remains an option for treatment of urinary tract infections in pregnant 
women, although due to its potential to cause harm its use should be reconsidered (van de Mheen et 
al., 2014). 
Two carbapenems, meropenem and imipenem-cilastatin, were used in this study. Carbapenems are 
broad-spectrum beta-lactams and are typically reserved for infections that are resistant to penicillin 
and cephalosporin antibiotic therapy (Heikkilä and Erkkola, 1994; Blanca-Lopez et al., 2019). The use 
of these antibiotics during pregnancy were minimal, indicating that they were possibly the only viable 
option available despite the paucity of safety data (Heikkila, Renkonen, and Erkkola, 1992; Mendelson 
et al., 2018). 
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Safety and efficacy information of antibiotics are usually very limited in pregnancy due to ethical 
implications around clinical testing in pregnant females. Some category B antibiotics such as 
phenoxymethylpenicillin, ceftriaxone, nitrofurantoin, metronidazole, and clindamycin are used, and 
are effective in pregnancy as also found in this study (Bookstaver et al., 2015). However, they cannot 
be classified as completely safe (Bookstaver et al., 2015). It has been reported that the use of 
clindamycin should be restricted, while the use of metronidazole in pregnancy is contra-indicated by 
the manufacturer (Rossiter, 2020). 
Approximately 11% of all antibiotics used were category C or D agents. Anti-mycobacterial agents, 
specifically the class of hydrazides and rifamycin, represented about 5% of the category C drugs. This 
is expected as just less than half of this study population are HIV-positive (Loto and Awowole, 2012). 
The burden of Tuberculosis (TB) has increased and trans-versed with the high incidence of HIV, as 75% 
of TB patients are HIV-infected. TB may be prevalent during pregnancy as a result of immunological 
changes, stress, and poor nutrition, particularly if there is an immunodeficiency or a co-existing 
disease. Studies have indicated that despite women being on combination ARV therapy, signs of TB 
may still appear. The WHO recommendation for treatment of TB in pregnant women is the same as 
for non-pregnant women and is based on standard therapy for six months, prolonged to a minimum 
of nine months (Adhikari, 2009). 
Restricted use among the other category C and D antibiotic classes were observed and anticipated as 
a result of restricted safety data and the possible teratogenic effects it may have on the foetus. A very 
small percentage of women in this study received these antibiotics. As aminoglycosides, 
fluoroquinolones, chloramphenicol, and trimethoprim-sulphonamide combinations are generally 
contraindicated in pregnancy unless the benefit of the drug exceeds the risk (Einarson, Shuhaiber, and 
Koren, 2001; Michalak et al., 2017; Yefet et al., 2018).  
Patients who were prescribed aminoglycosides and fluoroquinolones received them for the shortest 
possible duration. Research states that aminoglycosides should be avoided due to its potential to 
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cause ototoxicity, nephrotoxicity, and neuromuscular blockade. Only a few cases of neonatal 
ototoxicity have been recorded following short-term administration and the drug may be used in 
pregnant women with careful monitoring (Chow and Jewesson, 1985). It is advised that possible risks 
should be explained, especially in the first trimester. The use of fluoroquinolones in pregnancy remains 
controversial. In this study, only five patients of a total of 184 received a fluoroquinolone.  A systematic 
review by Yefet et al. assessed the safety of quinolones in pregnancy and reported no major congenital 
malformations (Yefet et al., 2018). The data suggest that, although fluoroquinolones were shown to 
cause possible harmful effects in some animal models, it is usually under higher concentrations. 
Although, in 2016, the FDA updated its warnings, for both oral and injectable fluoroquinolones (Acar 
et al., 2019). The authors illustrated that when the drug is used systemically, it may be associated with 
disabling and potentially permanent side effects, which can involve the disruption of tendons, joints, 
muscles, and nerves. Besides the effects mentioned, it could even induce type 2 diabetes. This was a 
result of an increase in the number of reports about fluoroquinolone toxicity and long-term 
complications. The FDA has since introduced significant restrictions to its use (Michalak et al., 2017; 
Yefet et al., 2018; Acar et al., 2019).   
Theoretically, sulphonamides are contra-indicated in the third trimester due to the potential risk of 
neonatal haemolysis, methemoglobinemia, and the fear of kernicterus, although practical evidence of 
this risk is sparse (Sivojelezova et al., 2003). In this study, seven prescriptions for trimethoprim-
sulphonamide combinations were dispensed to women who were in the third trimester of pregnancy 
for an average duration of 22 days. The use and long duration of this antibiotic might be due to the 
antibiotics beneficial uses exceeding its risk.  
Chloramphenicol is one of the few antibiotics that is completely avoided in pregnancy due to the risk 
of neonatal toxicity, particularly grey baby syndrome (Amstey, 2000; Chung and Kwok, 2004). It was 
observed that three patients received this drug for a duration of 28 days, although it was in the form 
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of an eye ointment. There is a very small probability that large amounts of the drug would be absorbed 
systemically which could harm the infant  (Chung and Kwok, 2004). 
According to several studies, the majority of antibiotics are used to treat genitourinary infections in 
pregnancy (Ghouri, Hollywood, and Ryan, 2019). Observantly, a large percentage of women in this 
study were treated predominantly for systemic infections, while infections of the genitourinary tract 
were the third most treated. This could be as a result of women attending a tertiary hospital for the 
treatment of more severe infections. 
Implications and recommendations 
There is currently a paucity of data regarding antibiotic use in pregnancy and further research should 
be done in this field. It is recommended that health care professionals keep abreast with new safety 
data that is continuously being published and incorporate that information into prescribing practices 
to ensure the safe use of antibiotics in this vulnerable population. It is also essential that more studies 
follow up on the side effects that drugs have on pregnant women. 
Limitations 
There are a few limitations to the study. The study was conducted in one site, in one town, and only 
included individuals that visited the hospital between January and July 2019 with a moderate study 
population. The results, therefore, cannot be extrapolated to either the national public/ private sector 
population or the general South African population. There were also very limited patient demographic 
data that could be extracted from patients’ records. There was inadequate time to follow up on those 
patients to identify whether their infants were affected by the antibiotic therapy that was received. 
Despite these limitations, this study contributes to research in this population group and builds on the 
evidence that currently exists. 
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Conclusion 
This study shows that despite the lack of clinical evidence, many classes of antibiotics are used in 
pregnancy apart from those with a safety record. The long-term reliance on antibiotics that are 
considered safer to use has led to emerging resistance resulting in the use of broad-spectrum or 
alternative agents where safety has not yet been established. Patients should be educated and 
encouraged to be a part of the decision-making process. The role of healthcare professionals in risk 
assessment and evaluation of available evidence for optimal antibiotic selection, dosing, duration of 
therapy, and monitoring is pertinent to improving maternal health. 
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Chapter 4: Manuscript II 
Introduction 
The experiences, attitudes, and beliefs of pregnant women towards the use of antibiotics are 
discussed in chapter four. A systematic approach was used to evaluate the risk-benefit perception of 
women regarding medicines during pregnancy.  
Chapter four is in manuscript format in accordance with the College of Health Sciences guidelines for 
dissertation submission at the University of KwaZulu-Natal (UKZN). 
This chapter is presented as a systematic review and was submitted for publication to the journal: 
BMC Systematic Reviews (Annexure 6). The protocol for the systematic review is also included in this 
chapter and was registered on Open Science Framework (OSF): Registration DOI: 
https://doi.org/10.17605/OSF.IO/SFZG3. The systematic review was written, formatted, cited, and 
referenced according to the journal’s submission guidelines. The author guidelines can be viewed in 
Annexure 7. 
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4.1 Systematic review protocol 
Title 
Awareness and risk perception of antibiotic use among pregnant women: A mixed-methods 
systematic review protocol 
Authors 
Sasha Naidoo; Henry Michael; Frasia Oosthuizen; Kofi Mensah 
Background and rationale 
The use of antibiotics in pregnancy is steadily increasing (Broe et al., 2014). However, antibiotics only 
account for a small percentage of the total congenital abnormalities experienced in pregnant women 
and the incorrect use or avoidance of these drugs may have life-threatening consequences (Zaki and 
Albarraq, 2014). 
In 2019, WHO predicted that more than 141 million children will be born, with approximately 200 
thousand maternal deaths occurring. Deaths among pregnant women are common in low-income 
countries (World Health Organization, 2019). In addition, an estimated 8 million infants are born with 
severe congenital disability (Haak and Radyowijati, 2003; World Health Organization, 2019). Low and 
middle-income countries in comparison to high-income countries, are more likely to be at risk from 
potential teratogens due to several socio-economic determinants. These may include low educational 
attainment, poverty, increased prevalence of infection, poor maternal nutrition, strained economies 
with poor regulation, and access to medication (Reardon et al., 2002; World Health Organization, 
2008). 
Literacy is an important socio-economic determinant that forms the foundation of health literacy 
(Sorensen et al., 2012). Health literacy among any population plays a significant role in understanding 
the risk of teratogenicity, obtaining health information, and making informed decisions (Kindig, 
Panzer, and Nielsen-Bohlman, 2004). For many individuals living in both, low income and middle-
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income countries, the lack of health literacy skills are a significant obstacle to effective health 
communication and contributes to higher maternal morbidity and mortality rates (Ngoh, 2009). 
Women in low-income countries that have sub-optimal literacy and health literacy, trust that if a 
healthcare professional prescribes a medicine, it is safe. They lack the need for health information, 
show poor ability to understand, are unaware of the adverse effects or risk it may accompany and are 
more likely to take a medicine that should be avoided, directly affecting maternal-foetal health (Ozawa 
and Walker, 2011; Dellicour et al., 2013; Lupattelli et al., 2014). 
In high-income countries, there is sufficient information to suggest that women are aware of the risk 
of medicines in pregnancy although they may perceive an unrealistic elevated risk which may influence 
the termination of a healthy pregnancy (Nordeng, Ystrom, and Einarson, 2010; Lupattelli et al., 2014). 
A misperception of elevated risk may also lead to inappropriate decisions regarding pregnancy 
outcomes (Damase-Michel et al., 2008). 
While there is substantial research that assess the awareness, knowledge, and perception of people 
regarding medicine use, to our knowledge there are no systematic reviews that focus on the 
teratogenic risk perception among pregnant women especially in resource poor settings, with high 
fertility rates and low literacy rates with minimal educational attainment (Csajka et al., 2014). The lack 
of disclosure by health care professionals regarding negative pregnancy outcomes may also impact 
the severity of the problem (Dellicour et al., 2013). 
It is imperative to understand the socio-cultural context and the perceived risk of potential teratogens 
among pregnant women to advocate correct antibiotic use. It is imperative that health care providers 
use evidence-based information to ensure effective communication, promote adherence, and provide 
safe and effective medicine use that contribute to improving maternal, neonatal, and child health 
(World Health Organization, 2008; Nordeng, Ystrom, and Einarson, 2010). 
 
 
77 
 
Review question  
What are the factors that determine the risk perception regarding antibiotic use among pregnant 
women and how does the perceived risk influence the use of antibiotics in this population?  
Aim 
The study aims to assess the use, knowledge, and beliefs of antibiotics among pregnant women and 
to compare disparities among low, middle, and high-income countries. 
Objectives 
• To assess the level of awareness regarding the risks and benefits of antibiotic use in pregnant 
women. 
• To evaluate the factors influencing the risk perception of antibiotic use in pregnant women. 
• To assess the relationship between risk perception and antibiotic use in pregnant women. 
Methodology 
The Joanna Briggs Institute (JBI) guidelines for mixed methods systematic reviews (MMSRs) will be 
followed from design to reporting (Johanna Brigg Institute, 2019). The review protocol will be 
registered on OSF (Open Science Framework, 2020).  
Eligibility criteria   
Inclusion Criteria  
The PICo framework will be used to determine the eligibility of this study. 
• P- Population/ participants: Pregnant women, ≥ 18 years old. 
• I- Phenomena of interest: Risk perception on antibiotic use. 
• Co- Context: Low-income countries, middle-income countries, and high-income countries. 
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Exclusion studies:  
• Studies that do not include pregnant women. 
• Non-English studies. 
• Studies not having the outcome of interest. 
Types of studies 
• This review will consider primary quantitative, qualitative, and mixed methods studies. 
Quantitative studies will include descriptive and analytical cross-sectional studies. Qualitative 
studies will include studies that are semi-structured, focus group discussions (FGD), individual, 
or one-on-one interviews. Mixed methods studies will only be considered if data from the 
quantitative or qualitative components can be extracted. 
• Only studies published in the English language will be included.  
• Studies published from 2000 to the present will be included to ensure relevance to current 
practice. 
Main outcomes 
• Risk perception scores of antibiotics in pregnant women. 
• Beliefs about antibiotic use in pregnancy. 
Secondary outcomes 
• Studies that have only perception of teratogenic risk as the outcome will be included. 
• Studies showing adherence to antibiotics as an outcome of risk perception will be included. 
• Studies showing factors influencing risk perception of antibiotic use in pregnancy. 
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Information sources  
A comprehensive search will be conducted using the following databases: PubMed (MEDLINE), 
Scopus, CINAHL, and Psycinfo. Google scholar will be accessed for grey literature. The references of 
selected studies will also be examined for other primary studies that may have been missed. 
Search strategy  
The search strategy will aim to locate both published and unpublished studies. An initial limited search 
of MEDLINE was undertaken to identify articles on the topic. The search strategy for MEDLINE via 
PubMed has been attached (Appendix 2). Keywords and free texts were developed for four themes: 
Antibiotics (also including ‘medicines’) to capture studies where antibiotics are discussed as sub-
themes, pregnancy, risk perception, and awareness. The search strategy, including all identified 
keywords and index terms, will be adapted for each included information source. 
Data selection and extraction 
Selection 
This systematic review will be assessed and completed by three reviewers (SN, HM, and KM). 
Screening of the title/ abstract and full article screening will be done independently by two reviewers 
for eligibility (SN and HM). The rate of the agreement will be calculated. Disagreements will be 
resolved by the third reviewer (KM). All identified citations will be exported into Mendeley and 
duplicates will be removed.  
Data extraction  
A standardised data extraction tool will be used to record the relevant information from the included 
studies. The tool will consist of: study title, authors, aim, year, country, sample size, sample description 
(age, gestational age, parity), data type (qualitative, quantitative, or mixed-methods), methodology 
for data collection (telephone, web-based, face-to-face, FGD), response rate, antibiotics, and 
references. Also, educational attainment/ level of knowledge, the perceived risk or benefit of medicine 
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use during pregnancy, and factors influencing perception. The key findings, study strengths, and 
limitations will also be extracted. Furthermore, qualitative data will comprise of themes or subthemes 
with corresponding illustrations. 
Data transformation 
The quantitative data will be converted into ‘qualitised data’. This involves transformation into 
thematic descriptions of the quantitative results from observational studies including the quantitative 
component of mixed methods studies in a way that will answer the review questions.  
Data synthesis and integration 
A convergent integrated approach will be applied according to the JBI methodology (Johanna Brigg 
Institute, 2019). This will involve assembling the ‘qualitised’ data with the qualitative data. The 
collected data will be categorised and pooled together based on similarity in meaning to produce a 
set of integrated results. 
Risk of Bias 
To assess the quality of the study, the Mixed Method Appraisal Tool (MMAT), version 2018 will be 
used (Hong et al., 2018). 
Analysis of subgroups or subsets 
Group-based patterns within and between studies affecting the risk perception of antibiotics in 
pregnant women will be noted. These may relate to geography, age, gestational age, and culture.  
Ethical consideration  
Ethical approval will not be required as no individual data will be used. The results will be disseminated 
by publication in a peer-reviewed journal.  
Study timeline  
October 2019 – January 2020 
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Study personnel  
Reviewer 1: Sasha Naidoo 
Reviewer 2: Henry Michael 
Reviewer 3: Dr Frasia Oosthuizen 
Review 4: Dr Kofi Mensah 
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Abstract 
Background 
The perception of risk significantly affects the decision to take an antibiotic during pregnancy. 
Understanding womens’ beliefs and their demographic and socio-cultural context allow for effective 
antibiotic treatment among this vulnerable population. This study aimed to explore the perceived risk 
of antibiotic therapy and to assess the factors that influence its use in the pregnant population.  
Method 
PubMed, Scopus, CINAHL, and Psycinfo were systematically searched by two reviewers for studies 
published between January 2000 to December 2019. The quality of the selected articles was critically 
appraised using a standardised tool. We stratified analysis according to themes based on the 
framework of the Health Beliefs Model (HBM). The PRISMA guidelines and JBI guidelines for mixed-
method systematic reviews were followed. 
Results 
A total of 1539 articles were identified, of which 14 studies met the inclusion criteria. The selected 
studies included four regions: Europe, America, Asia, and Africa. Limited studies were found in low 
and middle-income countries, especially among rural communities. The majority of women attained 
tertiary qualifications and expressed a misconceived belief of risk.  
Conclusion  
An unrealistic misconception of risk among pregnant women were observed in European and Asian 
studies, while a lack of safety and awareness of antibiotic use was discovered in an African population. 
A significant link between risk perception, educational attainment, and health literacy was found 
among the studies. 
 
 
86 
 
Keywords 
Risk, benefit, awareness, pregnancy, perception, beliefs, antibiotics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
Introduction 
The use of medicines in pregnancy is a cause for concern and uncertainty among women (1). Infection 
during pregnancy is common and may be inevitable, requiring the need for treatment. It is reported 
that between 62-80% of medication prescribed in pregnancy, is an antibiotic; hence one out of every 
four pregnant women is treated with one (2–4).  
Several concerns have been raised regarding the safety of antibiotics used in pregnancy (5–7). 
Antibiotics can be teratogenic or cause short- or long-term effects on the foetus. Some antibiotics are 
considered safer to use, while others are to be completely avoided. This raises the challenge of 
reaching the therapeutic concentration while avoiding the risk of adverse drug reactions that may 
harm the foetus; health care professionals therefore make decisions based on guidelines that allow 
them to weigh the benefits and risks against the severity of the illness (8–10).  
Womens’ beliefs and attitudes about medicine use are likely to significantly influence antibiotic 
therapy in pregnancy. The attitude and behaviour of pregnant women play an essential role, especially 
in circumstances when the untreated disease may be more harmful than the prescribed medicine. 
Pregnancy is a known determinant for poor medication adherence and several studies report that 
women have an unrealistic perception of risk regarding antibiotic use (11,12). The discernment of the 
patient may also vary depending on their level of health literacy, age, level of education, parity, 
geographical region, and most importantly their beliefs and opinions affecting their ability to make 
well-informed health decisions (11,13). 
A study conducted in the Netherlands concluded that most patients were “concerned” or “very 
concerned” about miscarriage and congenital disabilities. However, recent studies observed that 
women tend to overestimate the degree of teratogenic risk, a similarity found in several other high-
income countries (11,14). Womens’ perception of risk towards medicine in pregnancy thus is an 
important factor that affects the use of medication (12). 
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There is substantial research that assesses the awareness, knowledge, and perception of people 
regarding medicine use but to our knowledge, there are no systematic reviews that focus on the risk-
benefit perception of antibiotics among pregnant women, especially in resource-poor settings, with 
high fertility rates, low literacy rates, and minimal educational attainment (15). Understanding the 
socio-cultural context and the perceived risk of potential teratogens among pregnant women is crucial 
for advocating correct antibiotic use. 
The primary aim of the study is to assess knowledge and beliefs of antibiotic use in pregnant women, 
and to compare disparities among low, middle, and high-income countries by identifying the factors 
that determine the risk perception and evaluating its influence on the use of these drugs. 
Methods  
Protocol and registration 
The Joanna Briggs Institute (JBI) guidelines for mixed methods systematic reviews (MMSRs) and the 
Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines were followed from design to 
reporting (16). The review protocol was registered on Open Science Framework (OSF) (17). 
Registration DOI: https://doi.org/10.17605/OSF.IO/SFZG3  
Eligibility criteria 
Inclusion Criteria  
The PICo framework was used to determine the eligibility of this study. 
• P- Population/ participants: Pregnant women, ≥ 18 years. 
• I- Phenomena of interest: Risk perception of antibiotic use. 
• Co- Context: All countries; no restriction on geography. 
Studies were included if they were published in the English language, included pregnant women that 
were aged 18 years or older, and discussed the phenomena of interest. Only primary quantitative, 
qualitative, and mixed methods studies were included. Quantitative studies included descriptive and 
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analytical cross-sectional studies. Qualitative studies included studies that were semi-structured, 
involved focus group discussions (FGD), individual, or one-on-one interviews. 
Search strategy and sources 
A systematic search for studies from January 2000 to December 2019 were performed using four 
databases, which included PubMed, Scopus, CINAHL, and Psycinfo. The search strategy was piloted 
and approved by two reviewers SN and HM and composed of variations of the following search terms: 
risk, benefit, perception, awareness, pregnancy, and antibiotics. This search was conducted to acquire 
patient perspectives across all countries. An additional search for grey literature was conducted on 
Google Scholar and the references of these articles were searched.  
Study selection, quality appraisal, and data extraction 
Titles and abstracts were screened by two independent reviewers (SN and HM) and articles were 
selected for full screening based on the inclusion criteria. Full article screening was also independently 
done by both reviewers (SN and HM). Inter-rater reliability in the title/ abstract and full text screening 
were calculated using Cohen's kappa coefficient (κ). The included studies were assessed for quality 
using a standardised critical appraisal tool for mixed-method studies (MMAT) (Appendix 5) (18). A 
methodological selection of questions were used to assess each article. The quantitative and 
qualitative components were assessed separately using their respective tools. Every question had a 
response of “yes’’, ‘’no’’, or ‘’can’t tell’’. No articles were excluded based on low quality. An overall 
quality score could not be calculated using this tool.  
Data from the included studies were extracted by the primary reviewer (SN) using a data extraction 
template on Microsoft® Excel and later checked by the secondary reviewer (HM). Author’s name, year 
of publication, country, setting, study design, socio-demographic description, sample size, and the 
main findings were recorded. Additionally, educational attainment / level of knowledge, the perceived 
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risk or benefit of medicine use during pregnancy, factors influencing perception and limitations of the 
study were also recorded (Appendix 6).  
Data analysis, data transformation, and data integration 
The extracted data were arranged into various themes and subthemes that were similar among the 
selected studies. The data obtained from quantitative studies were transformed into ‘qualitised data’ 
by narrative and thematic synthesis. A convergent integrated approach was then applied according to 
the JBI methodology (16). This involved assembling the ‘qualitised’ data with the qualitative data to 
categorise and pool data based on similarity in meaning to produce a set of integrated results.  
The selected themes were based on the theoretical framework of the HBM. Key elements of this 
model focus on individual beliefs about health conditions, which predict individual health-related 
behaviours (19). The model defines the key factors that influence health behaviour and is divided into 
five main domains: perceived susceptibility, perceived severity, perceived benefits, perceived barriers 
to action, and exposure to factors that prompt action as shown in Figure 1 (19). A concept map was 
generated to show the theme linkage, shown in Figure 3. The primary themes are related to - trust, 
illness perceptions, perceived risk or benefit, and information sources.  
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Figure 1 A summary explaining the Health Beliefs Model (HBM) (19) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modifying factors 
• Geographic 
location 
• Age 
• Educational 
attainment 
• Health literacy 
• Occupation 
• Parity 
• Income  
Individuals behaviour 
 
5. Cues to action  
External factors affecting the individuals 
behaviour: Media, health personnel, 
family, friends, and dual illness.  
Individual beliefs 
1. Perceived susceptibility  
Is there awareness regarding the 
potential side effects of the 
antibiotic? 
2. Perceived severity  
Is the severity of the risk lower 
or higher than the actual risk?  
3. Perceived Benefit 
Is there awareness regarding the 
benefits of the antibiotic?  
4. Perceived barriers to action 
Were there obstacles preventing 
change in behaviour?  
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Results  
 The database search identified 1539 records. A total of 359 duplicate records were removed. One 
thousand one hundred and eighty (1180) articles were independently screened by authors SN and 
HM. One thousand one hundred and sixty-nine (1169) irrelevant articles were excluded. Eleven studies 
were retrieved from the four databases. An additional search from Google Scholar and the references 
of articles that were selected for full-text review yielded three results. Only 14 studies met the 
inclusion criteria for this review. The rate of agreement was calculated at each step to obtain an overall 
of 98.8% using Cohen's kappa coefficient (κ=0.82). Any disagreements were resolved by the third 
reviewer (KM). A flow chart summarising the selection process is shown in Figure 2 (20,21). 
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Figure 2 The systematic selection process reported according to PRISMA guidelines (20) 
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Study characteristics 
 The review included 14 studies that were published from the year 2000-2019. Nine (n=9) studies were 
published between the years 2012 and 2019. Most studies were carried out in Europe (n=9), with only 
a few studies conducted in America (n=1), Asia (n=3) and Africa (n=1). One study was a multinational 
study that included 18 countries in Europe. The studies were either qualitative, quantitative, or mixed-
methods cross-sectional studies. The sample size varied among the different articles. The mean 
sample size for participants in this study was 707, with a range of 20-4999 participants. The objectives 
of the studies differed significantly, although they included various multi-dimensional aspects of the 
risk or benefit of antibiotics. Only four studies focused primarily on antibiotic use in pregnancy, 
whereas others (n=10) included antibiotics as a sub-category. 
Socio-demographic variables  
Almost all the studies included participants that attained either high or middle education, with most 
women aged between 20-40 years. A significant portion of women who participated in the studies 
were in their third trimester and reported that they were previously pregnant with one or more 
children. Many of the studies were done in urban areas with only one study that recruited participants 
from predominantly rural settlements in Saudi Arabia. Additionally, only a single study was diverse in 
its recruitment as participants from urban, semi-rural, and rural areas from one private and one public 
hospital were selected. Women were selected from either obstetric care facilities or tertiary hospitals 
in eight studies (9,11,22–27), while the other studies included women that were active on different 
social media platforms and websites (12,28–32). The majority (n=9) of studies did not disclose whether 
their participants were employed, however, four studies did include participants that were and two 
of those studies included women that worked in the health care sector (11,23,29,32). Most of the 
studies included in this review consisted of similar population groups; only a single study consisted of 
a multicultural patient population with high levels of socio-economic deprivation and mixed 
educational backgrounds. 
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Table 1 Characteristics of included studies (n=14) 
Author and 
year 
Country Study design Sample 
size 
Aim Main findings 
Mulder et al. 
(2018) (11) 
Netherlands Quantitative 136 To evaluate the 
perception of risks 
and benefits of 
medication use during 
pregnancy and 
associations with 
socio-demographic 
characteristics. 
Most drugs were perceived 
relatively low in risk and 
high in benefit.  
Antibiotics had one of the 
highest benefit scores. The 
major concern of pregnant 
women was having a child 
with birth defects (35%), 
having a miscarriage (35%), 
and the future development 
of allergic diseases (23%).  
High-risk scores were 
reported more by women in 
the first trimester of 
pregnancy. 
Ghouri et al. 
(2019) (28) 
UK (England, 
Scotland, 
Wales, 
Northern 
Ireland) 
Qualitative 205 
threads 
from 675 
online 
users 
To explore womens’ 
experiences of UTIs in 
pregnancy, to develop 
an understanding of 
their concerns, and to 
encourage behaviours 
that facilitate the 
appropriate use of 
antibiotics. 
The main concern of the 
mother was the effect of 
the UTI on the foetus. A few 
women expressed 
reluctance and questioned 
the use of antibiotics during 
pregnancy. 
 A small proportion of 
women were uncertain of 
how the antibiotic might 
affect the foetus or their 
child’s immunity in the long 
term but for the remaining 
majority, antibiotics were 
perceived as the safest and 
most effective treatment.  
Alsaleh et al. 
(2019) (22) 
Saudi Arabia Quantitative 253 To assess the 
knowledge of 
pregnant women 
regarding the use and 
awareness of 
antibiotics. 
The educational level, 
economic level, and the 
stage of pregnancy 
significantly affected 
knowledge and awareness 
of antibiotic use, p=0.006, 
p=0.002, p=0,003. 
Women with a bachelor’s 
degree and a higher 
economic status had a 
higher awareness than 
other participants.  
Kenyon et al. 
(2006) (23) 
UK (A single 
region) 
Qualitative 20 To explore women’s 
experiences of being 
recruited to ORACLE, a 
randomised controlled 
Most women had the 
perception that there was a 
possible benefit to their 
babies and no harm. 
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trial of antibiotics in 
pre-term labour. 
Women were confident and 
trusting in their health 
professionals and reported 
that they were told there 
was no harm to the study. 
Bulabula et al. 
(2019) (24) 
South Africa  Quantitative  301 To establish the 
knowledge, attitudes, 
and practices (KAP) 
regarding antibiotic 
use and self- 
medication among 
pregnant women. 
Pregnant women with a 
lower K-score were most 
likely to self-medicate.  
More than half of the 
women disagreed with the 
statement that antibiotics 
should not be bought over 
the counter, with 17% 
purchasing antibiotics over 
the counter without a 
doctor’s prescription. While 
36% treated the flu with an 
antibiotic.  
Sanz et al. 
(2001) (25) 
Spain Quantitative 81 To assess the 
perception of 
teratogenic risk of 
common medicines by 
professionals and 
laypeople. 
The risk perception among 
pregnant women were over 
estimated. 
The true risk for amoxicillin 
and erythromycin were 
estimated to be <5%, while 
the perceived teratogenic 
risk was 40,4% and 38,7%.   
Mashayekhi 
et al. (2009) 
(26) 
Iran Quantitative 400 To obtain information 
regarding the 
awareness of Iranian 
pregnant women 
about the effects of 
drugs in pregnancy. 
It was found that 1-13%, 
perceived that antibiotics 
were safe in pregnancy, 
while the majority over-
estimated the risk of 
antibiotics. 
Zaki et al. 
(2014) (9) 
Saudi Arabia Quantitative 760 To assess medication 
use, knowledge, and 
beliefs about 
medications among 
pregnant women in 
Saudi Arabia. 
A large percentage (59%) of 
participants mentioned that 
all the antibiotics listed 
(penicillin, ampicillin, 
amoxicillin, cloxacillin, 
cephalosporins, 
erythromycin, gentamicin, 
amikacin, streptomycin, 
sulphonamides, and 
tetracyclines) should be 
avoided. 
It was reported that                                                                                                                
44.7% agreed that it was 
better for the foetus, if 
medicines are used than to 
have an untreated illness 
during pregnancy, while 
31% disagreed and 23,7% 
were uncertain.  
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Nordeng et al. 
(2010) (29) 
 
Norway  Quantitative 866 To assess pregnant 
womens’ beliefs about 
medications.  
Secondly, to 
investigate whether 
beliefs during 
pregnancy were 
associated with socio-
demographic 
characteristics and 
personal medication 
use during pregnancy. 
Significant associations 
were observed between 
education, occupation, and 
attitude.  
Less-educated women 
believed medicines were 
harmful and herbal 
remedies were safe.  
Women with higher 
education were more 
reluctant to use medicines 
during pregnancy.  
Women with health-related 
jobs were more 
knowledgeable about the 
risk of untreated illnesses.  
van Gelder et 
al. (2019) (30) 
Netherlands  Qualitative  1224 To evaluate the 
availability and 
accuracy of social 
media content on the 
perceived safety of 
medication use during 
pregnancy. 
A large proportion of the 
posts had contained 
inaccurate information 
regarding antibiotic use.  
It was reported that the 
over-estimation of safe 
medicines could affect 
adherence which could 
impair maternal or foetal 
health. 
Widnes et al. 
(2013) (27) 
Norway  Quantitative  171 The aim of the present 
study was to examine 
differences in risk 
perception between 
pregnant women and 
their corresponding 
general practitioners 
(GPs).  
Secondly to 
investigate confidence 
in medicine use during 
pregnancy, through 
texts from Patient 
Information Leaflets 
(PILs). 
Risk perception of the 
pregnant women were 
higher than the risk 
perception of their GP's 
with lowered confidence in 
use. 
PILs could influence patient 
adherence to prescribed 
medicines or recommended 
medicines in need of 
treatment. 
Nyholm et al. 
(2019) (12) 
Denmark  Qualitative  10 To explore in-depth, 
the perceptions of 
medication use among 
pregnant women 
during their 
pregnancy. 
 
 
 
Majority of women 
overestimated the risk.  
Women believed that it was 
less safe to take medicines 
during pregnancy.  
It was reported that 
conversations with 
physicians had a calming 
effect. 
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 Some women received 
conflicting information from 
the internet. 
Bonari et al. 
(2005) (31) 
Canada Quantitative  100 To determine the risk 
perception of 
antidepressants in 
comparison to 
antibiotics and gastric 
medications by 
pregnant women with 
depression.  
Secondly, to identify 
the determinants that 
influence women in 
their decision making 
regarding the 
continuation/ 
discontinuation of 
medication during 
pregnancy. 
There was a high initial risk 
perception.  
Despite receiving reassuring 
information, 15% of women 
chose to discontinue their 
medication as compared to 
1% of antibiotic users. 
Counselling had a major 
impact on medication 
continuation.  
The level of education, age, 
and other socio-
demographic factors did not 
correlate with the decision 
outcome in this study. 
Lupattelli et 
al. (2014) (32) 
America and 
Europe (18 
countries) 
Quantitative  4999 To explore the role of 
maternal health 
literacy in relation to 
perception of 
medication risk, 
beliefs about 
medication, and non-
adherence to 
prescribed 
pharmacotherapy 
during pregnancy. 
A high-risk perception score 
was determined for 
penicillin antibiotics.  
Majority of women had 
medium health literacy and 
high educational 
attainment.  
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Table 2 Sociodemographic characteristics of included studies (n=14) 
Study Socio-demographic characteristics 
 Geography Educational 
attainment 
Age/ age group 
(years) 
Mean trimester Parity 
Mulder et al. 
(2018) 
Europe 
(Netherlands) 
Middle-high 
educational level 
31 
- 
Third  Reportedly 
71.3% of 
women had 
children. 
Ghouri et al. 
(2019)  
Europe  
(UK) 
High (degree 
qualification) 
 
30-40 
 
- - 
Alsaleh et al. 
(2019)  
Asia 
 (Saudi-Arabia) 
Middle – high 20-40 
 
Third Reportedly 
64.6% of 
women had 
children. 
Kenyon et al. 
(2006)  
Europe  
(UK) 
Middle - Second and 
third 
The majority of 
women had 
children. 
Bulabula et al. 
(2019)  
Africa  
(South Africa) 
Middle 29 Second and 
third 
The majority of 
women had 
children. 
Sanz et al. 
(2001)  
Europe  
(Spain) 
- - - - 
Mashayekhi et 
al. (2009)  
Asia  
(Iran) 
High 20-29 - Half of the 
women had 
children. 
Zaki et al.  
(2014) 
Asia   
(Saudi Arabia) 
 
High 20–40 - The majority of 
women had 
children. 
Nordeng et al. 
(2010)  
Europe 
(Norway) 
High - - - 
van Gelder et al. 
(2019)  
Europe 
(Netherlands) 
 
- - - - 
Widnes et al. 
(2013)  
 
Europe 
(Norway) 
High 30 First and second The majority of 
women had 
children. 
Nyholm et al. 
(2019) 
Europe 
(Denmark) 
High 30 Third Most women 
were pregnant 
for the first 
time. 
Bonari et al. 
(2005) 
North America 
(Canada) 
- - - - 
Lupattelli et al. 
(2014) 
Europe  
(18 countries) 
Middle and high 25 Second 
 
Most women 
were pregnant 
for the first 
time. 
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Associations between perception and demographic variables 
Several population-based studies assessed the relationship between perception and the different 
demographic variables; educational attainment, economic level, trimester, and parity. 
Education and health literacy  
Multiple studies reported the educational level of the participants; however, only four of these studies 
investigated the direct influence of education or health literacy on risk perception (9,22,24,29). Most 
women in this study had medium health literacy and a high level of educational attainment. 
The level of education attained and its effect on knowledge and awareness regarding antibiotic use 
was significant in a Saudi Arabian study (p=0.006) (22). Women with tertiary education demonstrated 
higher awareness in comparison to the other participants, accompanied by an elevated perception of 
risk (9,24,29).  
Pregnant women with lower educational levels were more likely to be doubtful about drugs in 
comparison to those with higher education (32). Lupattelli et al. reported that low literate women 
were often younger, single, or divorced with no previous children compared to their adequately 
literate counterparts and were more likely to have a higher risk perception (32). In contrast, Bulabula 
et al. reported that almost 60% of women thought that it was acceptable to buy antibiotics over the 
counter, expressing a lower perception of risk (24).  
Other studies indicate that women with low or medium health literacy were more likely to be non-
adherent to prescribed systemic antibiotics. Women with higher education were more reluctant to 
use medication during pregnancy (9,29). This contrasting interpretation indicates that there was no 
unanimity regarding the association between risk perception and education among the different 
articles. 
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Economic level 
A significant association between the economic level of the women and the impact on knowledge and 
awareness were shown in two studies (22,24). The first study, is a cross-sectional study conducted in 
Saudi Arabia, which discussed that women who obtained a bachelor’s degree generally had a higher 
economic status, which was strongly associated with antibiotic awareness and subsequently 
knowledge (p=0.002) (22). Secondly, Bulabula et al. explained  that the economic level contributed to 
the reason for antibiotic use and whether it was used with or without a prescription (22).  
Trimester of pregnancy and parity 
Two studies reported the perceived risk scores of medicine use during the first two trimesters of 
pregnancy and it was shown that there were a significantly higher risk in the first and second trimester 
in comparison to the third trimester (p=0.003 and p=0.07) (11,22). Lower benefit scores of medicines 
were perceived if women were single and nulliparous (p=0.006) (11). In a South African cohort of 
pregnant women, the mean knowledge-score of antibiotic use and awareness was satisfactory and it 
was reported that pregnant women with a lower knowledge score were most likely to self-medicate 
with an antibiotic (24).  
Antibiotic prevalence and use  
The prevalence of antibiotic use was mentioned in six articles ranging from 2.6-33% 
(9,11,22,24,29,31). A variety of penicillins, nitrofurantoin, ciprofloxacin, erythromycin, metronidazole, 
and cephalosporins were some of the commonly reported antibiotics. Penicillins were mentioned in 
four studies (9,25,28,32). The risk perception for this class of antibiotics well exceeded its true risk in 
all four studies. 
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Factors that influenced risk perception  
The perception of risk was influenced by several contributing factors. These factors included the 
patient-physician relationship, perceived susceptibility to potential adverse reactions, the perceived 
severity of risk, and awareness regarding the benefits of antibiotic therapy. 
Patient-physician relationship and trust  
Patient-physician relationship was an overarching theme that was observed in two cross-sectional 
studies conducted among White European women (23,28). The level of education varied among the 
two studies (23,28). A qualitative analysis study by Ghouri et al. consisted of women that were 
predominantly tertiary graduates. In contrast, a qualitative study by Kenyon et al. included women 
that only completed secondary education, yet an element of trust was observed in both studies (28). 
Education was interlinked to the concept of trust. Women with a tertiary qualification trusted but 
were still aware of the possibility of harm, whereas women who obtained only secondary schooling 
also demonstrated a level of trust but lacked awareness and essential knowledge.  
Evidence:  
Ghouri et al. (2019) (28) 
''Doc wouldn't prescribe it, if it is dangerous.” 
''The doc said, it wouldn't do me any harm and it is better than not taking them, just in case I had needed them.” 
“I don’t think you should feel guilty as the doc would have given you antibiotics that wouldn’t affect your baby.’’ 
‘’Antibiotics are one of the few things that they are really sure about giving to pregnant women, precisely because we get 
infections.’’ 
‘’My doctor said it was safe to use the cystitis relief sachets along with drinking plenty of water and cranberry juice and 
apparently it should go within 48 hours.’’ 
Kenyon et al. (2006) (23) 
''At 32 weeks with [baby's name] and I was just kind of laying on the bed and the doctors came in and asked me if I wanted 
to take part in the trial. We just agreed straight away because we both felt that it was too early for him to be born and if 
there was a chance to stop it, we wanted to take it.''    
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‘’It's only antibiotics which a doctor would give you if you've got a cold or a cough. I just felt as if it couldn’t do us any harm 
and it wasn't causing either me or my baby any harm in any way.''       
Perceived susceptibility, implications of a dual risk, and prenatal attachment  
The concern of a dual risk was present in five studies from Europe and Asia, where women were highly 
educated (9,12,23,28,29). Women perceived the risk of taking antibiotics to be significantly high but 
were faced with a conflicting decision when experiencing an illness. The risk of an untreated illness 
was weighed against the possible effect of the antibiotic during pregnancy. Most women had doubts 
about using these medicines, but some identified with the benefits of the antibiotic in the event of an 
illness (12). The fear of the foetus being harmed by the illness was more of a concern than the side 
effects of the antibiotic primarily due to prenatal attachment (28). 
Evidence: 
 Ghouri et al. (2019) (28) 
''Hi, I'm 6 + 4 and had a scan today. I got to see a little heartbeat, but the only problem was traces of blood in my urine. They 
gave me antibiotics for what they suspect is a UTI. I am just worried now after seeing the heartbeat that taking the antibiotic 
will do something to the baby.''                                                                                                                                                                                                                                            
 "Untreated UTIs can lead to permanent kidney damage and premature labour. I’m not trying to scare you and I’m sure you’ll 
be fine, but could you get in touch with your MW [midwife] and get their opinion."         
''Doc wouldn't prescribe if it is dangerous. It's more dangerous to leave a UTI, as at its worst it can cause kidney issues and 
miscarriage.’’            
Nyholm et al. (2019) (12) 
‘’Most women had doubts about using medicines, but some said that medicines should not be avoided at all cost. A few said 
that if a medicine needed to treat a disease was avoided, it could cause harm to the child. Some said it would be better for 
the mother to get well instead of being ill.’’ 
‘’I have been on penicillin during pregnancy because it’s not beneficial if I’m ill. It is better to get over it. For example, if I have 
a urinary tract infection, it’s not good for the foetus, it makes my uterus hard and the only way to treat it, is with medicine.’’      
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Medicine Information sources   
Multiple studies integrated the different sources of information that were referred to by the women. 
Gynaecologists, general physicians, pharmacists, and mid-wives were the most commonly consulted 
health personnel, although, one study mentioned a lack of direction or advice from physicians (31). 
Others obtained information from PILs, family, friends, and the internet. It was reported that some 
information on social platforms may be inaccurate and predominantly highlights the risks of antibiotics 
compared to the benefits (9,11,26,27,29–31). Counselling was proven to be beneficial in two studies, 
enhancing adherence and demonstrating a decline in comparison to the initial risk perception (31,33). 
Perceived severity of risk 
The perceived risk among the majority of the studies (n=10) were reportedly higher than the actual 
risk (9,12,22,25,26,28–32). Women were most concerned about congenital anomalies, miscarriage, 
premature birth, and the long-term effects that the antibiotic may have on the developing foetus 
(11,12,23,28).  
Evidence: 
Ghouri et al. (2019) (28) 
''Personally, I would be wary of it [antibiotics] because there is a link between taking antibiotics in the late stages of pregnancy 
and the baby having eczema or allergies. I took antibiotics in late pregnancy and my daughter has multiple food allergies and 
eczema.''    
"Cranberry juice is good as well. If it is mild this may flush the infection out and is gentler than antibiotics, which will be likely 
to cause thrush.''      
''I'm petrified that taking amoxicillin will harm the baby!''    
Nyholm et al. (2019) (12) 
‘’The majority of women felt that medicines could have unknown long-term adverse effects on their baby for example: heart 
failure, reduced fertility, social difficulties in school, growth disorders, asthma, and allergies.’’ 
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"If there is some kind of revelation that is not discovered yet, it is possible that in 20 years from now there might be a higher 
risk for something we do not know yet."         
Nordeng et al. (2010) (29) 
“Reportedly 87% agreed that they were more cautious about using medicines when they were pregnant. While 61,5% agreed 
that if they were ill and not pregnant, they would have taken medicines, but it was better to abstain. However, 87,4% agreed 
that they have a higher threshold for medicines when pregnant.’’ 
‘’Reportedly 43,4% agreed that all medicines can be harmful for the foetus.’’ 
Perceived benefits of antibiotic treatment  
Despite the significant number of women who have acquired a high-risk perception towards the use 
of antibiotics, some women still recognised the benefits of these drugs. Five studies included 
participants that were aware of the risk of antibiotics but also mentioned the benefits (9,11,23,28,29). 
Evidence:  
Ghouri et al. (2019) (28) 
‘’I’m surprised that they haven’t given you any antibiotics straight away as it can cause early labour or a small baby if left 
untreated. Mine’s been in my kidneys, the pain has been horrendous. Don’t suffer if you need to ring and ask for antibiotics.’’ 
Kenyon et al. (2006) (23) 
‘’I was all for it. They found out that antibiotics do help. It’s therefore helping thousands of women, isn't it? "     
Nordeng et al. (2010) (29) 
‘’Reportedly, 42,1% agreed that treatment with medicines during pregnancy saves the lives of unborn children.’’ 
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Figure 3 A concept map summarising risk perception in this review 
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Discussion 
This systematic review aimed to assess the knowledge, beliefs, and practice of antibiotics among the 
pregnant population. To our knowledge, this is the first mixed-methods systematic review to 
investigate the risk perception of antibiotic use in pregnant women. Most individuals believed that 
antibiotics were detrimental during pregnancy and should be avoided, while others recognised the 
advantages.  
Risk perception is a multi-dimensional precursor to understanding health behaviour in preventing risk 
(34). This multi-faceted concept revealed that the perception related to medicines significantly 
depended on an individual’s geographical region, education, and health literacy. In addition, the HBM 
was utilised to provide a cohesive overview of the perceived susceptibility, severity, and benefits of 
antibiotic use (35).  
Firstly, the perceived risk of antibiotic use among pregnant patients in this study was closely linked to 
a women’s level of education. There was sufficient information to suggest that women with a higher 
degree of educational attainment in high-income countries were more often fearful and were more 
likely to over-estimate the risk in comparison to the actual risk profile of the medicine. This agrees 
with the concept explained in a recent article by Bonari et al. which discusses that the apparent 
fallacious perception of risk regarding medication, is strongly influenced by the phenomenon of 
probability, which proves to conceive a notion of unrealistically high-risk perceptions (11,13,33).  
Most women believed that antibiotics were teratogenic and may have future adverse effects on the 
foetus. Miscarriage, premature birth, and congenital abnormalities were some of the prime concerns 
mentioned. However, an American journal affirms that only 1% of all birth defects are as a result of 
maternal drug use. Only a few medicines have been proven as teratogenic (FDA classified category D 
and category X drugs), with studies reporting that the risk of malformation for most drugs, do not 
exceed the baseline figures of 2- 4% (25,27,36). Notably, in several studies, penicillin, an FDA classified 
category B antibiotic, was grouped as having the same risk in comparison to confirmed teratogens, 
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known to be strictly avoided in pregnancy. This indicates that many women with high educational 
attainment still collectively group all these drugs as being harmful, a commonality also found in 
another study (11). Adequate or high educational attainment, therefore, does not necessarily 
translate to a high health literacy level (9,29). A misperception of elevated risk may lead to 
inappropriate decisions regarding pregnancy outcomes that may lead to poor adherence, 
discontinuation of treatment, and even the termination of a healthy and wanted pregnancy (37).  
In some studies, it was observed that although women may perceive an unrealistic elevated risk, they 
are still aware of the benefits of medicines in pregnancy, especially women in health-related 
occupations. They showed a more positive attitude towards medicines as they acquired a higher 
degree of health literacy, allowing for a more educated and informed perception in comparison to 
other women (9,11,29).  
Women with lower educational attainment also demonstrated a high-risk perception and agreed that 
medicines did more harm than good, were addictive, and poisonous. They were more skeptical about 
drugs in comparison to those with higher education (9). Although, a Kenyan study reported that 
women show reluctance to take a medicine that may be beneficial, not because they are aware of the 
risk of the medicines, but because the drug predisposes them to nausea and vomiting, which may 
contribute to this negative belief (38). 
Secondly, the behaviour and perception of antibiotic use were largely influenced by the risk of an 
untreated maternal ailment. The distress of a dual risk gave a false sense of perception among studies 
as the perceived risk of antibiotics appeared to be low. However, this was not the case as the perceived 
risk still remained high, but the concern of having an illness that had the possibility to worsen was 
greater (9,12,23,28,29).  
Thirdly, trust in health personnel was a pertinent factor that affected health behaviour.  A single study 
reported that women felt that antibiotics were one of the few things that clinicians were sure about 
prescribing to pregnant women. This revealed that some women were confident in their health care 
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professionals. Women from both high and low educational backgrounds displayed a significant level 
of trust. Women from higher educational backgrounds may not necessarily be more health literate, 
but they are aware of the possibility of experiencing side effects. In contrast, females with inadequate 
education, living in rural communities that comprise of predominantly low literate individuals, also 
display significant levels of trust but they have limited or no knowledge of drug safety and the possible 
adverse drug reactions. They firmly believe that if a healthcare professional prescribes a medicine, it 
is safe. They lack the need for health information, show poor ability to understand, and are more likely 
to take a medicine that should be avoided, directly affecting maternal-foetal health (7,38,39). A study 
that was conducted in the Vientiane Capital, Lao explains a similar phenomenon (40).  
A serious concern among women in low and middle-income countries was low risk perception and 
self-medication. Bulabula et al. reported that almost 20% of women purchased antibiotics over the 
counter or without a medical prescription to treat the common cold or flu during pregnancy (24). 
Women in these communes lack essential knowledge and skills to make educated decisions. They 
would instead prefer to consume a traditional herbal remedy, considering its use safer than taking 
medicine prescribed by a health care professional. This could suggest a lack of trust in the health care 
domain especially in developing areas, although this concept needs to be investigated further (41,42).  
An Ethiopian study revealed that more than half of the women who were pregnant used over the 
counter medicines and the majority of those were antibiotics (43). This behaviour may be a 
commonality in other low-middle income countries; however, further research is required. Women 
are, therefore, at a higher risk of experiencing possible adverse effects despite the low percentage of 
congenital anomalies (40,41). A recent study conducted in Ghana reported that about 94% of infants 
born with birth defects were reported to come from low and middle-income countries. In the event 
that an abnormality does occur, it was perceived by society that this socially marginalised group had 
engaged in some taboo or incest, resulting in the abnormality (38,44). However, there is limited 
information relating to risk perception and pregnancy in developing countries.  
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The concern of self-medication in these poorer communities may also contribute to the crisis of 
antibiotic resistance. Antibiotic resistance is steadily increasing in low and middle-income societies 
and is a global challenge associated with high morbidity and mortality rates (45). 
Lower risk perception was also noticed in women who were previously pregnant and had one or more 
children in comparison to nulliparous women. Women in the third trimester of pregnancy 
demonstrated a lower risk perception and were more willing to consider the benefits of antibiotics 
(9,11,22,24,26,27,32). 
Lastly, the persuasive nature of the internet and media played a significant role in a women’s decision 
considering its rapid response to obtaining information. Women used this platform as a reference for 
medical information, contributing to the issue of receiving conflicting information that is most often 
not evidence-based (9,11,24,26,28–30). Studies revealed that women also acquired information from 
PILs although this source may provide restricted and indefinite evidence, in a language that may be 
too complex for patients to understand (12,46). This negatively shapes the perspective of both the 
health care professional and the patient. This is evident in a study by Widnes et al. which reported 
unrealistically high-risk perception among physicians. At the same time, pregnant women reported 
with an even higher misperception compared to their physicians. The lack of factual sources of 
information may be a reason for this (36). 
Health care professionals have an essential role to play when advocating the use of medication in 
pregnancy. This is critical, especially when pregnant women are diagnosed with an infection and 
require antibiotic therapy to lower the risk of miscarriage, abortion, or preterm birth in contrast to 
dealing with the complications of the antibiotic (13).  
In this review, counselling was proven to have a beneficial effect on lowering risk perception. Mulder 
et al. revealed that women were convinced more easily to identify with the health benefits of certain 
medicines, such as antibiotics, as compared to other classes of medicines (33). The provision of 
positively framed advice and information by physicians and pharmacists can affect a patient’s 
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perception allowing for the evaluation of the medicines advantageous uses rather than focusing on 
the possibility of harm. Individually tailored information provided by drug information centres and full 
disclosure by health care professionals regarding adverse pregnancy outcomes contributes to this goal 
(11,38). 
Literacy and health literacy among any population plays a significant role in understanding the risk of 
teratogenicity, obtaining health information, and making informed choices (47). Literacy forms the 
foundation of health literacy, which has been closely linked to perception and beliefs. According to 
WHO, Africa has a 65% literacy rate as compared to the 94% literacy rate in America, with two-thirds 
of this percentage being women (48,49). For many individuals living in both, low-income and high-
income countries, the lack of health literacy skills are a significant obstacle to effective health 
communication (50). 
Educating women in rural and poor societies about the danger of self-medication, possible uses, and 
side effects of antibiotics in a language that is understood by them may improve health literacy among 
these vulnerable populations. It is also necessary to address the general fear and hesitation of 
antibiotics in low, middle, and high-income populations allowing them to obtain a more realistic 
perception. 
There is currently limited research regarding the effect of socio-demographic characteristics on the 
knowledge and the practice of antibiotic use in the pregnant population. Understanding potential 
misconceptions and identifying existing gaps will contribute to the development of necessary 
interventions to encourage practical and prudent use of antibiotics.   
Limitations 
A few limitations were identified throughout this study. This review was done using a relatively limited 
number of databases for the identification of potentially eligible studies. A substantial number of 
studies were conducted in high-income European countries, with only a few studies investigating risk 
 
112 
 
perception in middle-income countries while no studies were obtained from low-income societies. 
The included studies lacked diverse, multi-ethnic, and multi-racial population groups with varying 
levels of socio-economic standing and educational backgrounds as the majority of the participants 
were European women having obtained tertiary education. Risk perception of antibiotic therapy was 
not a focus instead was common sub-category in most of the studies. This study was only confined to 
the English language and excluded unpublished articles; hence results cannot be generalised.  
Conclusion  
The majority of women in high-income countries with high educational attainment, having some 
degree of health literacy were persuaded by the prospect of risk, resulting in an over-estimated risk 
perception. Women with lower educational levels in rural low-income societies with minimal or no 
health literacy were more likely to be submissive and unfamiliar with the concern of risk. These two 
extremities of risk perception negatively affect the use of antibiotics and may result in sub-optimal 
therapy. It is imperative that health care providers use evidence-based information to ensure effective 
communication, promote adherence, and provide safe and effective medicine use that contribute to 
improving maternal, neonatal, and child health (51,52). 
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Chapter 5: Conclusion 
The final chapter highlights the overall findings of the study, describes the limitations and significance 
of the study, in addition to providing recommendations for future research. 
5.1 Summary of findings  
The aim of this study was to evaluate the use of antibiotics among pregnant women. To achieve this, 
the following objectives were met: 
• Quantifying antibiotic use in pregnant patients. 
• Commenting on the rationale for antibiotic use among pregnant patients. 
• Evaluating the safety profile of antibiotics used during pregnancy. 
• Determining the risk perception of antibiotics among pregnant women in both low,    
               Middle, and high-income countries using a systematic approach. 
Conclusions were drawn and summarised based on each objective.  
• Penicillins were quantified as the most used antibiotic in pregnancy and accounted for 39.7% of 
prescriptions followed by macrolides (13%) and combination penicillin-and-beta-lactam inhibitors 
(12.3 %). Phenoxymethylpenicillin was the most prescribed penicillin. Azithromycin was the only 
macrolide used among this population and amoxicillin/ clavulanic acid combination was the most 
prescribed penicillin-and-beta-lactam inhibitor. Polymyxins were the least prescribed antibiotic 
class among the pregnant women.  
• Almost 40% of antibiotics were prescribed for infections of the blood and circulatory system with 
13% of prescriptions been dispensed for genitourinary tract infections. The remainder were for 
bacterial complications that implicated the endocrine and metabolic system (6.33%), nervous 
system (5.53%), skin and tissue (4.09%) and the respiratory tract (3.13%).  
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• Penicillins are considered to be the safest antibiotic used in pregnancy with no reported 
teratogenic effects. Macrolides and nitrofurantoin show a growing concern regarding safety in the 
pregnant population with carbapenems having limited safety data. Other classes such as 
metronidazole and clindamycin are used and are effective in pregnancy, however they cannot be 
classified as completely safe.  
• An unrealistic perception of risk among pregnant women were observed in European and Asian 
studies, while a lack of safety and awareness of antibiotic use was discovered in an African 
population. A significant link between risk perception, educational attainment, and health literacy 
were found among the studies.  
5.2 Significance of the study 
This study signifies the importance of drug safety and pharmacovigilance in pregnancy. Regardless of 
the limited availability of safety evidence, antibiotics are still commonly used to treat pregnant 
women. The appropriate and correct use of antibiotics are crucial to ensure that the mother and 
foetus are not harmed, there is improvement in maternal health, and use of these drugs are judicious. 
The study also signifies the importance of understanding how women perceive the use of antibiotic 
therapy and the influence of risk perception on medicine behaviour, adherence, and non-adherence. 
5.3 Strengths 
The studies contribute to and strengthens existing literature while addressing the gaps in the current 
knowledge of antibiotic safety and risk perception in pregnancy. The findings of this study can assist 
health care prescribers to be more aware when prescribing and ensure the effective use of antibiotics 
through positive communication.  
5.4 Limitations 
The quantitative study was restricted to a single tertiary hospital in the public sector; hence the trends 
and use of antibiotics in pregnant women from private-sector institutions were not taken into 
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consideration. Additionally, time constraints prevented the collection of data over a longer period. 
The systematic review was limited in its selection of databases and was restricted to only published 
studies which were of the English language; hence unpublished studies and studies of other languages 
were excluded. 
5.5 Recommendations  
• This study was restricted to one tertiary hospital in the public sector. Further studies should 
focus on hospitals in the private sector as well as hospitals in other provinces to get a 
broader perspective on antibiotic use and prescribing in pregnant women.  
• Antibiotic resistance is an emerging issue that significantly affects the use of antibiotics in 
pregnant women and hence further research should be conducted in this field.  
• Health care professionals need to keep abreast with new evidence that becomes available 
on the safety of antibiotics.  
• Future studies should focus on the attitude and perception of antibiotics in pregnant women 
in low and middle-income countries as limited research exists in these settings.  
Chapter summary 
The final chapter highlighted the important aspects of the study and identified the gaps in the 
current literature with future recommendations.  
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Annexure 5: Submission guidelines for Health SA Gesondheid 
Overview 
The author guidelines include information about the types of articles received for publication and 
preparing a manuscript for submission. Other relevant information about the journal's policies and 
the reviewing process can be found under the about section. The compulsory cover letter forms part 
of a submission and must be submitted together with all the required forms. All forms need to be 
completed in English. 
  
 Original Research Article 
 
An original article provides an overview of innovative research in a particular field within or related to 
the focus and scope of the journal, presented according to a clear and well-structured format. See full 
structure of original research articles below. 
  
Word limit 5000 words (excluding the structured abstract and references) 
Structured abstract 250 words to include a Background, Aim, Setting, Methods, 
Results, Conclusion and Contribution 
References 40 or less 
Tables/Figures no more than 7 Tables/Figure 
Ethical statement should be included in the manuscript 
 
A systematic review follows the same basic structure as an original research article: 
• Structured abstract: Background, aim, setting, methods, results, conclusion, contribution. 
• Aim and objectives: Focus on a clinical question that will be addressed in the review. 
• Methods section: Describe in detail the search strategy, criteria used to select or reject articles, 
attempts made to obtain all important and relevant studies and deal with publication bias (including 
grey and unpublished literature), how the quality of included studies was appraised, the methodology 
used to extract and/or analyse data. 
• Results: Describe the homogeneity of the different findings; clearly present the overall results and any 
meta-analysis. 
  
 Review Article 
 
Review topics should be related to clinical aspects interdisciplinary health sciences and should reflect 
trends and progress or a synthesis of data in the following format. See full structure of review articles 
below. Systematic reviews are considered under original research. 
  
Word limit 4000 words (excluding the abstract and references) 
References 40 or less 
Abstract up to 150 words, unstructured 
Tables/Figures data in the text should not be repeated extensively in tables or 
figures 
  
Editorial 
 
Editorials are by invitation only and are intended to provide expert comment on relevant topics within 
the focus and scope of the journal: 
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Word limit 1200 words 
Tables/Figures a maximum of 1 figure or table 
References 10 or less 
Conclusion ensure that there is a clear message in the conclusion 
  
Cover Letter 
 
The format of the compulsory cover letter forms part of your submission. Kindly download and 
complete, in English, the provided cover letter. 
  
Anyone that has made a significant contribution to the research and the paper must be listed as an 
author in your cover letter. Contributions that fall short of meeting the criteria as stipulated in our 
policy should rather be mentioned in the ‘Acknowledgements’ section of the manuscript. 
Read our authorship guidelines and author contribution statement policies. 
  
 Original Research Article full structure 
 
Title: The article’s full title should contain a maximum of 95 characters (including spaces). 
  
Abstract: The abstract, written in English, should be no longer than 250 words and must be written in 
the past tense. The abstract should give a succinct account of the objectives, methods, results and 
significance of the matter. The structured abstract for an Original Research article should consist of 
six paragraphs labelled Background, Aim, Setting, Methods, Results and Conclusion. 
• Background: Summarise the social value (importance, relevance) and scientific value (knowledge gap) 
that your study addresses. 
• Aim: State the overall aim of the study. 
• Setting: State the setting for the study. 
• Methods: Clearly express the basic design of the study, and name or briefly describe the methods used 
without going into excessive detail. 
• Results: State the main findings. 
• Conclusion: State your conclusion and any key implications or recommendations. 
• Contribution: Concise statement of the primary contribution of your manuscript. 
Do not cite references and do not use abbreviations excessively in the abstract. 
  
Introduction: The introduction must contain your argument for the social and scientific value of the 
study, as well as the aim and objectives: 
• Social value: The first part of the introduction should make a clear and logical argument for the 
importance or relevance of the study. Your argument should be supported by use of evidence from 
the literature. 
• Scientific value: The second part of the introduction should make a clear and logical argument for the 
originality of the study. This should include a summary of what is already known about the research 
question or specific topic and should clarify the knowledge gap that this study will address. Your 
argument should be supported by use of evidence from the literature. 
• Conceptual framework: In some research articles it will also be important to describe the underlying 
theoretical basis for the research and how these theories are linked together in a conceptual 
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framework. The theoretical evidence used to construct the conceptual framework should be 
referenced from the literature. 
• Aim and objectives: The introduction should conclude with a clear summary of the aim and objectives 
of this study. 
Research methods and design: This must address the following: 
• Study design: An outline of the type of study design. 
• Setting: A description of the setting for the study; for example, the type of community from which the 
participants came or the nature of the health system and services in which the study is conducted. 
• Study population and sampling strategy: Describe the study population and any inclusion or exclusion 
criteria. Describe the intended sample size and your sample size calculation or justification. Describe 
the sampling strategy used. Describe in practical terms how this was implemented. 
• Intervention (if appropriate): If there were intervention and comparison groups, describe the 
intervention in detail and what happened to the comparison groups. 
• Data collection: Define the data collection tools that were used and their validity. Describe in practical 
terms how data were collected and any key issues involved, e.g. language barriers. 
• Data analysis: Describe how data were captured, checked and cleaned. Describe the analysis process, 
for example, the statistical tests used or steps followed in qualitative data analysis. 
• Ethical considerations: Approval must have been obtained for all studies from the author's institution 
or other relevant ethics committee and the institution’s name and permit numbers should be stated 
here. 
• Results: Present the results of your study in a logical sequence that addresses the aim and objectives 
of your study. Use tables and figures as required to present your findings. Use quotations as required 
to establish your interpretation of qualitative data. All units should conform to the SI convention and 
be abbreviated accordingly. Metric units and their international symbols are used throughout, as is 
the decimal point (not the decimal comma). 
 
Measures of Trustworthiness: This refers to the findings of the study being based on the discovery of 
human experience as it was experienced and observed by the participants. The following are the 
criteria of trustworthiness, credibility, transferability, dependability and confirmability to be 
discussed. 
  
Reliability: Reliability is the extent to which an experiment, test, or any measuring procedure yields 
the same result with repeated trials. Without the agreement of independent observers able to 
replicate research procedures or the ability to use research tools and procedures that yield consistent 
measurements, researchers would be unable to satisfactorily draw conclusions, formulate theories or 
make claims about the ability to generalise their research. 
  
Validity: Validity refers to the degree to which a study accurately reflects or assesses the specific 
concept that the researcher is attempting to measure. While reliability is concerned with the accuracy 
of the actual measuring instrument or procedure, validity is concerned with the study's success at 
measuring what the researchers set out to measure. Researchers should be concerned with both 
external and internal validity. External validity refers to the extent to which the results of a study are 
generalisable or transferable. Internal validity refers to: 
• The rigor with which the study was conducted (e.g. the study's design, the care taken to conduct 
measurements and decisions concerning what was and was not measured). 
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• The extent to which the designers of a study have taken into account alternative explanations for any 
causal relationships they explore. 
Discussion: The discussion section should address the following four elements: 
• Key findings: Summarise the key findings without reiterating details of the results. 
• Discussion of key findings: Explain how the key findings relate to previous research or to existing 
knowledge, practice or policy. 
• Strengths and limitations: Describe the strengths and limitations of your methods and what the reader 
should take into account when interpreting your results. 
• Implications or recommendations: State the implications of your study or recommendations for future 
research (questions that remain unanswered), policy or practice. Make sure that the 
recommendations flow directly from your findings. 
Conclusion: Provide a brief conclusion that summarises the results and their meaning or significance 
in relation to each objective of the study. 
 
Acknowledgements: Those who contributed to the work but do not meet our authorship criteria 
should be listed in the Acknowledgments with a description of the contribution. Authors are 
responsible for ensuring that anyone named in the Acknowledgments agrees to be named. Refer to 
the acknowledgement structure guide on our Formatting Requirements page. 
  
Also provide the following, each under their own heading: 
• Competing interests: This section should list specific competing interests associated with any of the 
authors. If authors declare that no competing interests exist, the article will include a statement to 
this effect: The authors declare that they have no financial or personal relationship(s) that may have 
inappropriately influenced them in writing this article. Read our policy on competing interests. 
• Author contributions:  All authors must meet the criteria for authorship as outlined in 
the authorship policy and author contribution statement policies. 
• Funding: Provide information on funding if relevant 
• Data availability: All research articles are encouraged to have a data availability statement. 
• Disclaimer: A statement that the views expressed in the submitted article are his or her own and not 
an official position of the institution or funder. 
References: Authors should provide direct references to original research sources whenever possible. 
References should not be used by authors, editors, or peer reviewers to promote self-interests. Refer 
to the journal referencing style downloadable on our Formatting Requirements page. 
  
 Review Article full structure 
 
Title: The article’s full title should contain a maximum of 95 characters (including spaces). 
  
Abstract: The abstract should be no longer than 250 words and must be written in the past tense. The 
abstract should give a concise account of the objectives, methods, results and significance of the 
matter. The abstract can be structured and should consist of five paragraphs labelled Background, 
Aim, Method, Results and Conclusion. 
• Background: Why is the topic important to us? State the context of the review 
• Aim: What is the purpose of your review? Describe the aim or purpose of your review. 
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• Method: How did you go about performing the review? Describe the methods used for searching, 
selecting and appraising your evidence. 
• Results: What are the findings? What are the main findings of your literature review? 
• Conclusion: What are the implications of your answer? Briefly summarise any potential implications. 
• Contribution: Concise statement of the primary contribution of your manuscript. 
Introduction: Present an argument for the social and scientific value of your review that is itself 
supported by the literature. Present the aim and objectives of your literature review. 
  
Methods: Although this is not a systematic review (see instructions on original research for this type 
of article) it is still necessary to outline how you searched for, selected and appraised the literature 
that you used. Discuss any methodological limitations. 
  
Review findings: Present your review of the literature and make use of appropriate sub-headings. 
Your review should be a critical synthesis of the literature. 
  
Implications and recommendations: Discuss the findings of your review in terms of the implications 
for policy makers and clinicians or recommendations for future research. 
  
Conclusion: This should clearly state the main conclusions of the review in terms of addressing the 
original aim and objectives. 
  
Acknowledgements: Those who contributed to the work but do not meet our authorship criteria 
should be listed in the Acknowledgments with a description of the contribution. Authors are 
responsible for ensuring that anyone named in the Acknowledgments agrees to be named. Refer to 
the acknowledgement structure guide on our Formatting Requirements page. 
  
Also provide the following, each under their own heading: 
• Competing interests: This section should list specific competing interests associated with any of the 
authors. If authors declare that no competing interests exist, the article will include a statement to 
this effect: The authors declare that they have no financial or personal relationship(s) that may have 
inappropriately influenced them in writing this article. Read our policy on competing interests. 
• Author contributions:  All authors must meet the criteria for authorship as outlined in 
the authorship policy and author contribution statement policies. 
• Funding: Provide information on funding if relevant 
• Data availability: All research articles are encouraged to have a data availability statement. 
• Disclaimer: a statement that the views expressed in the submitted article are his or her own and not 
an official position of the institution or funder. 
  
References: Authors should provide direct references to original research sources whenever possible. 
References should not be used by authors, editors, or peer reviewers to promote self-interests. Refer 
to the journal referencing style downloadable on our Formatting Requirements page. 
Style and format 
 
File format 
• Manuscript files can be in the following formats: DOC, DOCX, or RTF. Microsoft Word documents 
should not be locked or protected. 
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• LaTeX documents (.tex) should be converted into Microsoft Word (.doc) before submission online. 
• Rich Text Format (RTF): Users of other word processing packages should save or convert their files to 
RTF before uploading. Many free tools are available that will make this process easier. 
 
Length 
Manuscripts should adhere to the author guidelines of the journal. There are restrictions on word 
count, number of figures, or amount of supporting information. 
  
Font 
Use a standard font size and any standard font family. 
  
Special characters 
Do not use the font named ‘Symbol’. To add symbols to the manuscript, use the Insert → Symbol 
function in your word processor or paste in the appropriate Unicode character. Refer to our AOSIS 
house style guide on mathematical and Unicode font guidelines. 
  
Headings 
Ensure that formatting for headings is consistent in the manuscript. Limit manuscript sections and 
sub-sections to four heading levels. To avoid confusion during the review and production process, 
ensure that the different heading levels used in your work are visually distinct from one another. The 
simplest way to achieve this is to use different font sizes and/or a combination of bold/italics for 
different heading levels. 
  
Keywords 
Identify eight keywords that represent the content of your manuscript and are specific to your field or 
sub-field, ensure to separate each keyword with a semi-colon. Test your keywords: when you enter 
your keywords into the various journal and academic databases like Google Scholar, do the results 
include papers similar to your topic? If not, revise the terms until they do. 
  
Layout and spacing 
Manuscript text should have a 1.5 line spacing. 
  
Page and line numbers 
Include page numbers and line numbers in the manuscript file. Use continuous line numbers (do not 
restart the numbering on each page). 
  
Footnotes 
Footnotes are not ideal. If your manuscript contains footnotes, move the information into the main 
text or the reference list, depending on the content. 
  
Language 
Manuscripts must be written in British English, according to the Oxford English Dictionary (avoid 
Americanisms [e.g. use ‘s’ and not ‘z’ spellings] and set your version of Microsoft Word default 
language to UK English). Refer to the AOSIS house style guide for more information. 
  
Abbreviations 
Define abbreviations upon first appearance in the text. Do not use non-standard abbreviations unless 
they appear at least three times in the text. Keep abbreviations to a minimum. 
  
Illustrations 
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• Tables and/or Boxes: Text and/or numbers arranged in orderly columns and rows. 
Every time a Figure, Table and/or Box is presented in your manuscript, it should be referred to three 
times: 
• In a legend, which includes a number, a title, and its source. The legend is placed below a Figure and 
above a Table and/or Box. The source section should consist of the in-text citation, creator or owner 
and its year of creation, and any other attribution required as stipulated by the permission received 
(person and place) to reproduce. 
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about the image explaining what it illustrates and why it is there. 
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AOSIS house style 
The manuscript must adhere to the AOSIS house style guide. 
  
Referencing style guide 
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Preparing your manuscript 
The information below details the section headings that you should include in your manuscript and 
what information should be within each section. 
Please note that your manuscript must include a 'Declarations' section including all of the subheadings 
(please see below for more information). 
Title page 
The title page should: 
• present a title that includes, if appropriate, the study design e.g.: 
o "A versus B in the treatment of C: a randomized controlled trial", "X is a risk factor for 
Y: a case control study", "What is the impact of factor X on subject Y: A systematic 
review" 
o or for non-clinical or non-research studies a description of what the article reports 
• list the full names, institutional addresses and email addresses for all authors 
o if a collaboration group should be listed as an author, please list the Group name as 
an author. If you would like the names of the individual members of the Group to be 
searchable through their individual PubMed records, please include this information 
in the “Acknowledgements” section in accordance with the instructions below 
• indicate the corresponding author 
Abstract 
The Abstract should not exceed 350 words. Please minimize the use of abbreviations and do not cite 
references in the abstract. Reports of systematic reviews should follow the PRISMA extension for 
abstracts. The abstract must include the following separate sections: 
• Background: the context and purpose of the study 
• Methods: how the study was performed and statistical tests used 
• Results: the main findings 
• Conclusions: brief summary and potential implications 
• Systematic review registration: if your systematic review is registered in a publicly accessible 
registry, include the name of the registry and registration number. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background 
The Background section should explain the background to the study, its aims, a summary of the 
existing literature and why this study was necessary or its contribution to the field. 
Methods 
The methods section should include: 
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• the aim, design and setting of the study 
• the characteristics of participants or description of materials 
• a clear description of all processes, interventions and comparisons. Generic drug names 
should generally be used. When proprietary brands are used in research, include the brand 
names in parentheses 
• the type of statistical analysis used, including a power calculation if appropriate 
Results 
This should include the findings of the study including, if appropriate, results of statistical analysis 
which must be included either in the text or as tables and figures. 
Discussion 
This section should discuss the implications of the findings in context of existing research and highlight 
limitations of the study. 
Conclusions 
This should state clearly the main conclusions and provide an explanation of the importance and 
relevance of the study reported. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and a list of 
abbreviations should be provided. 
Declarations 
All manuscripts must contain the following sections under the heading 'Declarations': 
• Ethics approval and consent to participate 
• Consent for publication 
• Availability of data and materials 
• Competing interests 
• Funding 
• Authors' contributions 
• Acknowledgements 
• Authors' information (optional) 
Please see below for details on the information to be included in these sections. 
If any of the sections are not relevant to your manuscript, please include the heading and write 'Not 
applicable' for that section.  
Ethics approval and consent to participate 
Manuscripts reporting studies involving human participants, human data or human tissue must: 
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• include a statement on ethics approval and consent (even where the need for approval was 
waived) 
• include the name of the ethics committee that approved the study and the committee’s 
reference number if appropriate 
Studies involving animals must include a statement on ethics approval and for experimental studies 
involving client-owned animals, authors must also include a statement on informed consent from the 
client or owner. 
See our editorial policies for more information. 
If your manuscript does not report on or involve the use of any animal or human data or tissue, please 
state “Not applicable” in this section. 
Consent for publication 
If your manuscript contains any individual person’s data in any form (including any individual details, 
images or videos), consent for publication must be obtained from that person, or in the case of 
children, their parent or legal guardian. All presentations of case reports must have consent for 
publication. 
You can use your institutional consent form or our consent form if you prefer. You should not send 
the form to us on submission, but we may request to see a copy at any stage (including after 
publication). 
See our editorial policies for more information on consent for publication. 
If your manuscript does not contain data from any individual person, please state “Not applicable” in 
this section. 
Availability of data and materials 
All manuscripts must include an ‘Availability of data and materials’ statement. Data availability 
statements should include information on where data supporting the results reported in the article 
can be found including, where applicable, hyperlinks to publicly archived datasets analysed or 
generated during the study. By data we mean the minimal dataset that would be necessary to 
interpret, replicate and build upon the findings reported in the article. We recognise it is not always 
possible to share research data publicly, for instance when individual privacy could be compromised, 
and in such instances data availability should still be stated in the manuscript along with any conditions 
for access. 
Data availability statements can take one of the following forms (or a combination of more than one 
if required for multiple datasets): 
• The datasets generated and/or analysed during the current study are available in the [NAME] 
repository, [PERSISTENT WEB LINK TO DATASETS] 
• The datasets used and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
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• All data generated or analysed during this study are included in this published article [and its 
supplementary information files]. 
• The datasets generated and/or analysed during the current study are not publicly available 
due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author 
on reasonable request. 
• Data sharing is not applicable to this article as no datasets were generated or analysed during 
the current study. 
• The data that support the findings of this study are available from [third party name] but 
restrictions apply to the availability of these data, which were used under license for the 
current study, and so are not publicly available. Data are however available from the authors 
upon reasonable request and with permission of [third party name]. 
• Not applicable. If your manuscript does not contain any data, please state 'Not applicable' in 
this section. 
More examples of template data availability statements, which include examples of openly available 
and restricted access datasets, are available here. 
BioMed Central also requires that authors cite any publicly available data on which the conclusions of 
the paper rely in the manuscript. Data citations should include a persistent identifier (such as a DOI) 
and should ideally be included in the reference list. Citations of datasets, when they appear in the 
reference list, should include the minimum information recommended by DataCite and follow journal 
style. Dataset identifiers including DOIs should be expressed as full URLs. For example: 
 
Hao Z, AghaKouchak A, Nakhjiri N, Farahmand A. Global integrated drought monitoring and prediction 
system (GIDMaPS) data sets. figshare. 2014. http://dx.doi.org/10.6084/m9.figshare.853801 
With the corresponding text in the Availability of data and materials statement: 
The datasets generated during and/or analysed during the current study are available in the [NAME] 
repository, [PERSISTENT WEB LINK TO DATASETS]. 
If you wish to co-submit a data note describing your data to be published in BMC Research Notes, you 
can do so by visiting our submission portal. Data notes support open data and help authors to comply 
with funder policies on data sharing. Co-published data notes will be linked to the research article the 
data support (example). 
For more information please email our Research Data Team. 
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See our editorial policies for a full explanation of competing interests. If you are unsure whether you 
or any of your co-authors have a competing interest please contact the editorial office. 
Please use the authors initials to refer to each authors' competing interests in this section. 
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group of authors can clearly be associated with a web link, such as for weblogs, then they should be 
included in the reference. 
Example reference style: 
Article within a journal 
Smith JJ. The world of science. Am J Sci. 1999;36:234-5. 
Article within a journal (no page numbers) 
Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, Tjønneland A, et al. Meat 
consumption and mortality - results from the European Prospective Investigation into Cancer and 
Nutrition. BMC Medicine. 2013;11:63. 
Article within a journal by DOI 
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. Dig J Mol Med. 2000; 
doi:10.1007/s801090000086. 
Article within a journal supplement 
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Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic activity by bone 
marrow scan. Blood 1979;59 Suppl 1:26-32. 
Book chapter, or an article within a book 
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon 
KW, editors. International review of cytology. London: Academic; 1980. p. 251-306. 
OnlineFirst chapter in a series (without a volume designation but with a DOI) 
Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess and chiral 
symmetry breaking. Top Curr Chem. 2007. doi:10.1007/128_2006_108. 
Complete book, authored 
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 
3rd ed. Oxford: Blackwell Science; 1998. 
Online document 
Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society 
of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999. 
Online database 
Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. http://www.healthwise.org. Accessed 
21 Sept 1998. 
Supplementary material/private homepage 
Doe J. Title of supplementary material. 2000. http://www.privatehomepage.com. Accessed 22 Feb 
2000. 
University site 
Doe, J: Title of preprint. http://www.uni-heidelberg.de/mydata.html (1999). Accessed 25 Dec 1999. 
FTP site 
Doe, J: Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt (1999). Accessed 12 Nov 1999. 
Organization site 
ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 20 Feb 2007. 
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Dataset with persistent identifier 
Zheng L-Y, Guo X-S, He B, Sun L-J, Peng Y, Dong S-S, et al. Genome data from sweet and grain sorghum 
(Sorghum bicolor). GigaScience Database. 2011. http://dx.doi.org/10.5524/100012. 
Figures, tables and additional files 
See General formatting guidelines for information on how to format figures, tables and additional 
files. 
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Appendices 
Appendix 1: Data collection template 
Data collection template  
Site: Inkosi Albert Luthuli Hospital  
Date: 
Time:   
Time period: January – July 2019 
Inclusion Criteria:  
• Female  
• Pregnant  
• 18 years of age and over  
• Treated with an antibiotic  
 
Collected by:  
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Appendix 2: Search Strategy for Medline via Pubmed 
Theme 1: Risk perception  
Risk *OR benefit* AND perception* OR perceived  
Theme 2: Pregnancy  
Pregnancy OR pregnant OR ante-natal OR antenatal 
Theme 3: antibiotics 
Antibiotic* OR anti-bacterial OR antibacterial OR drug* OR medicine* OR medication 
Theme 4: awareness 
Awareness   
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Appendix 3: PRISMA checklist 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
2-3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
3-4 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
4-5 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
4 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving 
rationale.  
4-5 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
4-7 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
33-34 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
4-5 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
5-6 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
4-7 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used 
in any data synthesis.  
6 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
 
Synthesis of 
results  
14 Describe the methods of handling data and combining results 
of studies, if done, including measures of consistency (e.g., I2) 
6 
 
147 
 
for each meta-analysis.  
 
Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
8-9 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
10,11,25-
28 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  
 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally 
with a forest plot.  
11, 25-28 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
12-18 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
19-24 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
24 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
24 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review.  
25 
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Appendix 4: Search strategy for the systematic review 
Date Database searched Search Strategy Number of results 
Original search    
21/10/19 Medline via Pubmed ((((((((((Risk *[Text 
Word] OR 
benefit*[Text Word])) 
AND (perception*[Text 
Word] OR 
awareness[Text Word] 
OR perceived[Text 
Word]))) AND 
(pregnancy[Text Word] 
OR pregnant[Text 
Word] OR ante-
natal[Text Word] OR 
antenatal[Text 
Word]))) AND 
(antibiotic*[Text 
Word] OR anti-
bacterial[Text Word] 
OR antibacterial[Text 
Word] OR drug*[Text 
Word] OR 
medicine*[Text Word] 
OR medication[Text 
Word])))) AND ( 
"2000/01/01"[PDat] : 
"2019/12/31"[PDat] ) 
AND English[lang]) Sort 
by: Best 
Match Filters: Publicati
on date from 
2000/01/01 to 
2019/12/31; English 
 
 
1003 
 
22/10/19 scopus Risk W/3 perception 
AND (pregnancy OR 
263 
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pregnant) AND 
antibiotic* 
Limited to 2000-2019 
english 
22/10/19 Psychinfo  
(risk perception or 
perceived risk) AND 
(pregnancy or 
pregnant) AND 
(antibiotics or 
antibacterial or 
antimicrobials or drugs 
or medicines) 
Limited 2000-2019 
English only 
 
195 
23/10/19 
 
CINAHL (risk perception or 
perceived risk) AND 
(pregnancy or 
pregnant) AND 
(antibiotics or 
antibacterial or 
antimicrobials or drugs 
or medicines) 
Limited 2000-2019 
English only 
78 
    
Total before duplicates   1539 
Number of duplicates   358 
Total after de-
duplication 
  1181 
Articles selected after 
title and abstract 
screening  
  42  
(1139 did not meet the 
inclusion criteria) 
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Articles selected after 
full screening 
  11 
24/10/18 Grey literature- Google 
scholar 
Risk perception of 
antibiotics in pregnancy 
 
3 
   14 
    
 
Appendix 5: Critical appraisal tool (MMAT) for the systematic review is attached as a supplementary 
file. 
Appendix 6: Data extraction template for the systematic review is attached as a supplementary file. 
 
 
 
 
 
 
 
 
 
 
